NetSol (NTWK) Awarded Agreement Valued in Excess of $10 Million

Agreement Transforms Client’s Entire Business and IT Processes

CALABASAS, Calif., June 20, 2013 (GLOBE NEWSWIRE) — NetSol Technologies, Inc. (Nasdaq:NTWK), a worldwide provider of global IT and enterprise application solutions, today announced that it has signed a new agreement valued at more than $10 million to implement the complete front and back office modules of the NetSol Financial Suite^TM Platform for a major global auto captive finance Company. The customer’s name was not disclosed because of non-disclosure agreements in place.

NetSol said the implementation has already begun and shall consist of several delivery phases beginning later this calendar year. The contract includes product licenses, business processes consultancy and site implementation services. Additional revenue streams include maintenance, support and product enhancements.

Recently, NetSol has actively engaged with the client in a business process mapping and re-engineering program, which has yielded significant alignment and efficiencies. The new agreement is an outcome of this process and is expected to yield a state of the art technology platform and also introduce a number of best practices within the organization. The agreement is one of the most comprehensive NetSol has signed to date and is in keeping with NetSol’s growth strategy and market leading position of a product offering that aligns business and IT process change.

“Our agreement represents a major business transformation program that will touch almost every part of our client company, and shall bring change, visibility and tangible, measurable business results,” said Naeem Ghauri, President and Head of Global Sales of NetSol. “This is a game changing agreement and will most likely grow in value and volume, as we anticipate it will be followed by a decade-long program of committed support and enhancements.”

“We look forward to building a long term relationship with our new client to support their growth within the original country of implementation and potentially in various new markets,” added Najeeb Ghauri, CEO of NetSol. “We are excited to begin this new relationship and thank them for their trust in our technology and company.”

About NetSol Financial Suite ^TM

NetSol Financial Suite (“NFS”) is a robust suite of five software applications, an end-to-end solution for the lease and finance industry covering the complete leasing and finance cycle starting from quotation origination through end of contract. The NFS Suite consists of 60 modules grouped in five comprehensive applications. The five software applications under NFS have been designed and developed for a highly flexible setting and are capable of dealing with multinational, multi-company, multi-asset, multi-lingual, multi-distributor and multi-manufacturer environments. Each application is a complete system in itself and can be used independently to address specific sub-domains of the leasing/financing cycle. When used together, they fully automate the entire leasing / financing cycle.

About NetSol Technologies

NetSol Technologies, Inc. (www.netsoltech.com) is a worldwide provider of global IT and enterprise application solutions that include credit and finance portfolio management systems, SAP consulting and services, custom development, systems integration, and technical services for the global Financial, Leasing, Insurance, Energy, and Technology markets. Headquartered in Calabasas, Calif., NetSol’s product and services offerings have achieved ISO 9001, ISO 20000, ISO 27001, and SEI (Software Engineering Institute) CMMI (Capability Maturity Model) Maturity Level 5 assessments, a distinction shared by only 178 companies worldwide. The company’s clients include Fortune 500 manufacturers, global automakers, financial institutions, utilities, technology providers, and government agencies. NetSol has delivery and support locations in San Francisco, London, Beijing, Bangkok, Lahore, Sydney and Riyadh.

Forward-Looking Statements

This press release may contain forward-looking statements relating to the development of the Company’s products and services and future operation results, including statements regarding the Company that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words “expects,” “anticipates,” variations of such words, and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Factors that could affect the Company’s actual results include the progress and costs of the development of products and services and the timing of the market acceptance. The subject Companies expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

ChinaEdu (CEDU) Announces Receipt of “Going Private” Proposal

BEIJING, June 20, 2013 /PRNewswire/ — ChinaEdu Corporation (“CEDU”) (“ChinaEdu” or the “Company”), a leading online educational services provider in China, today announced that its board of directors has received a preliminary, non-binding proposal letter dated June 20, 2013 from Julia Huang, executive chairman of the board of directors and Shawn Ding, CEO of the Company (collectively, the “Buyer Parties”), to acquire all of the outstanding ordinary shares of the Company not currently owned by the Buyer Parties and certain other shareholders of the Company who may join the Buyer Parties, including ordinary shares represented by the Company’s American depositary shares, or “ADSs” (each representing three ordinary shares of the Company), at a proposed price of $2.33 in cash per ordinary share, or $7.00 in cash per ADS, subject to certain conditions.

According to the proposal letter, the acquisition is intended to be financed by debt and/or equity capital and the Buyer Parties have been in discussions with one or more financial institutions which have expressed interest in financing the proposed acquisition. Furthermore, the proposal letter specifies that the Buyer Parties’ proposal constitutes only a preliminary indication of its interest, and is subject to negotiation and execution of definitive agreements relating to the proposed transaction. A copy of the proposal letter is attached hereto as Exhibit A.

The Company’s board of directors intends to form a special committee of disinterested directors to consider the proposal and cautions the Company’s shareholders and others considering trading in its securities that the board of directors has just received the proposal and has not made any decisions with respect to the Company’s response to the proposal. There can be no assurance that any definitive offer will be made by the Buyer Parties or any other person, that any definitive agreement will be executed relating to the proposed transaction, or that this or any other transaction will be approved or consummated.

About ChinaEdu

ChinaEdu Corporation is an educational services provider in China, incorporated as an exempted limited liability company in the Cayman Islands. Established in 1999, the Company’s primary business is to provide comprehensive services to the online degree programs of leading Chinese universities. These services include academic program development, technology services, enrollment marketing, student support services and finance operations. The Company’s other lines of businesses include the operation of private primary and secondary schools, online interactive tutoring services and providing marketing, support for international and elite curriculum programs and online learning community for adult students.

The Company believes it is the largest service provider to online degree programs in China in terms of the number of higher education institutions that are served and the number of student enrollments supported. The Company currently has entered into collaborative alliances with 13 universities, ranging from 15 to 50 years in length. The Company has also entered into technology agreements with 8 universities. Besides, ChinaEdu performs recruiting services for 23 universities through a nationwide learning center network.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals, and projections, which are subject to numerous assumptions, risks, and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties and contingencies, many of which are beyond our control which may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The Company’s actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including those described under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2012, and in documents subsequently filed by the Company from time to time with the Securities and Exchange Commission. Unless required by law, the Company undertakes no obligation to (and expressly disclaim any such obligation to) update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:

Helen Plummer
Senior Investor Relations Coordinator
ChinaEdu Corporation
Phone: +1 908-442-9395
E-mail: helen@chinaedu.net

Simon Mei
Chief Financial Officer
ChinaEdu Corporation
Phone: +86 10 8418-7301
E-mail: simon@chinaedu.net

Exhibit A

The Board of Directors
ChinaEdu Corporation
4th Floor-A, GeHua Building
No. 1 Qinglong Hutong, Dongcheng District
Beijing 100007
People’s Republic of China

Dear Sirs:

Julia Huang (“Ms. Huang”), executive chairman of the board of directors of ChinaEdu Corporation (the “Company”) and Shawn Ding (“Mr. Ding”), CEO of the Company (collectively, the “Buyer Parties”), are pleased to submit this preliminary, non-binding proposal to acquire all outstanding ordinary shares (the “Shares”) and the American Depositary Shares (“ADSs”, each representing three Shares) of the Company, in both cases, that are not beneficially owned by the Buyer Parties and certain other shareholders of the Company who may join the Buyer Parties (the “Acquisition”).

We believe that our proposal of US$2.33 in cash per Share, or US$7.00 in cash per ADS, will provide an attractive opportunity to the Company’s shareholders. This price represents a premium of approximately 20% to the closing price of the Company’s ADSs on June 19, 2013 and a premium of approximately 22% to the volume weighted average price of the Company’s ADSs for the last 180 trading days.

1. Consortium. The Buyer Parties intend to work with each other exclusively in pursuing the Acquisition during the course of the transaction. Please also note that the Buyer Parties are currently only interested in pursuing the Acquisition and have no interest in selling their ordinary shares in any other transaction involving the Company.
2. Purchase Price. The Buyer Parties are prepared to pay for the Shares and ADSs to be acquired in the Acquisition at a price of US$2.33 per Share and US$7.00 per ADS, as the case may be, in cash.
3. Funding. It is intended that the Acquisition will be funded by debt and/or equity capital. We expect definitive commitments for the required debt financing and/or equity funding, subject to terms and conditions set forth therein, to be in place when the Definitive Agreements (as defined below) are signed.
4. Due Diligence. We will be in a position to commence our due diligence for the Acquisition immediately upon receiving access to the relevant materials. We believe that we will be in a position to complete customary legal, financial and accounting due diligence for the Acquisition in a timely manner and in parallel with discussions on the Definitive Agreements.
5. Definitive Agreements. We are prepared to promptly negotiate and finalize definitive agreements (the “Definitive Agreements”) providing for the Acquisition and related transactions. These Definitive Agreements will include representations, warranties, covenants and conditions which are typical, customary and appropriate for transactions of this type.
6. Process. We recognize that the Company’s Board of Directors (the “Board”) will evaluate the Acquisition independently before it can make its determination to endorse it. Given the involvement of Mr. Ding and Ms. Huang in the Acquisition, we appreciate that the independent members of the Board will proceed to consider the proposed Acquisition and that Mr. Ding and Ms. Huang will recuse themselves from participating in any Board deliberations and decisions related to the Acquisition.
7. Advisors. The Buyer Parties have retained Loeb & Loeb LLP as U.S. legal counsel in connection with the Acquisition.
8. Confidentiality. We are sure you will agree with us that it is in all of our interests to ensure that we proceed in a confidential manner, unless otherwise required by law or mutually agreed to by the parties, until we have executed the Definitive Agreements or terminated our discussions.
9. No Binding Commitment. This letter constitutes only a preliminary indication of our interest, and does not constitute any binding commitment with respect to the Acquisition. A binding commitment will result only from the execution of Definitive Agreements, and then will be on terms and conditions provided in such documentation.

In closing, we would like to express our commitment to working together to bring this Acquisition to a successful and timely conclusion. Should you have any questions regarding this proposal, please do not hesitate to contact us. We look forward to hearing from you.

Celsion’s (CLSN) ThermoDox® HEAT Study Reviewed at 2013 EU Oncology Conference

Duration of RFA Procedure Correlates with Meaningful Clinical Benefit

LAWRENCEVILLE, N.J., June 20, 2013 /PRNewswire/ — Celsion Corporation (NASDAQ: CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, 2013 ECIO Program Co-Chairman and the Director of the Division of Diagnostic Imaging and Intervention at Pisa University School of Medicine in Italy and Lead European Principal Investigator for the  HEAT Study reviewed the clinical trial results from the Company’s Phase III HEAT Study including findings from the HEAT Study post-hoc analysis at the 2013 European Conference on Interventional Oncology, which is being held June 19-22, 2013 in Budapest, Hungary.  The emerging post-hoc findings suggest that the heating cycles can be optimized to markedly improve radiofrequency ablation (RFA) when used with ThermoDox®.  The post-hoc data indicates that ThermoDox® may provide potential for clinically relevant improved progression free survival (PFS) and Overall Survival (OS) outcomes.  Professor Lencioni made two presentations on hepatocellular carcinoma (HCC) and related advances in interventional management.

• Professor Lencioni’s first presentation, titled “New Interventional Oncology Approaches in HCC; An Update on Clinical Trials” was held on Wednesday, June 19, 2013 at 2:30 p.m. (local time) in Plenary Session: Open Issues in the Management of Liver Cancer.  This presentation is part of a joint symposium of the ECIO and the International Liver Cancer Association (ILCA).  This special event will be chaired by Professor Lencioni (2013 ECIO Program Co-Chairman) and Dr. Joseph Llovet (ILCA President)
• His second presentation, titled “Thermally Sensitive Doxorubicin Carriers” was held on Thursday, June 20, 2013 at 10:30 a.m. (local time) in Plenary Session: New Horizons in Interventional Oncology

“I am pleased to present this post-hoc analysis of a large subgroup of patients from the Phase III HEAT Study to the European and international interventional oncology community which may be indicating a meaningful clinical benefit in both progression free survival (PFS) and overall survival (OS) in patients who received an optimized RFA procedure,” said Professor Lencioni.  “It is important to note the duration of heat from the RFA procedure is a key factor in a successful clinical outcome when combined with ThermoDox®. These findings are consistent with our understanding that increased perfusion and associated heating time are important factors for ensuring that the heat-sensitive liposomes are activated to deposit high concentrations of doxorubicin in the tumor and the surrounding liver tissue.”

The data from the HEAT Study post-hoc analysis presented by Professor Lencioni demonstrate that ThermoDox® markedly improves PFS and OS in patients with a single lesion if their lesions undergo RFA for 45 minutes or more. These findings apply to HCC lesions regardless of size and represent a subgroup of approximately 300 patients or 42% of the patients in the HEAT Study.

• In the patient subgroup treated in the ThermoDox® arm whose RFA procedure lasted longer than 45 minutes and was completed within 90 minutes (40% of single lesion patients) Overall Survival improved by 66% (Hazard Ratio of 0.602) when compared to the control arm of RFA treatment only.
• In the patient subgroup treated in the ThermoDox® arm whose RFA procedure lasted longer than 90 minutes (23% of single lesion patients), Overall Survival almost doubled (Hazard Ratio of 0.508) when compared to the control arm of RFA treatment only.
• When combined, these two subgroups show clinical results that indicated a 53% improvement in Overall Survival, a Hazard Ratio of 0.65, and a P_value = 0.105.
• In contrast, the patient subgroup treated with ThermoDox® whose RFA procedure lasted less than 45 minutes in duration (37% of single lesion patients) indicated that the control arm had an improved Overall Survival benefit when compared to the ThermoDox® arm.
• The Hazard Ratios reported above should be viewed with caution since they are not statistically significant and the HEAT Study has not reached its median point for Overall Survival analysis.  Celsion will continue following all patients enrolled in the HEAT Study to the secondary endpoint, Overall Survival, and update its subgroup analysis based on RFA heating duration.

Professor Lencioni’s presentation is available on the Company’s website at www.celsion.com under “News & Investor Info – Events & Presentations.”

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; termination of the Technology Development Contract or collaboration between Celsion and HISUN at any time; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion ‘s periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact
Jeffrey W. Church
Sr. Vice President — Corporate
Strategy and Investor Relations
609-482-2455
jchurch@celsion.com

Ligand (LGND) Raises Ownership Limit for BVF Partners to 25% of Shares Outstanding

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its Board of Directors has agreed to waive certain “poison pill” provisions to allow BVF Partners L.P., including its affiliates and associates (“BVF”), to increase its ownership of the Company from the previous limit of 19.99% of outstanding common stock to a new limit of 24.99%, subject to certain conditions. BVF has been Ligand’s largest shareholder since the second quarter of 2011 and currently owns 17.7% of the Company’s outstanding stock.

BVF’s acquisition of stock, if any, is expected to be made in the open market or through direct purchases from other stockholders. Ligand has been diligent in setting the terms of the waiver for the potential benefit of all shareholders of Ligand. In summary, the conditions under which BVF will be permitted to exceed the current limit of 19.99% and own up to 24.99% of Ligand’s outstanding stock include the following:

• BVF’s purchases must exceed the 19.99% threshold within nine months from the date of the agreement, or the waiver for the increased ownership limit automatically terminates.
• At any time BVF holds a position in excess of 19.99% of Ligand’s outstanding stock, Ligand’s Board of Directors will have sole voting control over BVF-owned shares representing 15% of the company’s total outstanding shares (currently approximately 3 million shares).
• BVF will not attempt to nominate any Director to the Ligand Board of Directors or undertake any other control initiative.
• Any shares purchased in excess of 19.99% of the outstanding common stock must be held by BVF for a minimum of four years or until the stock reaches $100 per share.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company that develops and acquires assets it believes will generate royalty revenues and, under its lean corporate cost structure, produce sustainable profitability. Ligand has a diverse asset portfolio addressing the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, diabetes, hepatitis, muscle wasting, dyslipidemia, anemia and osteoporosis. Ligand’s Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world’s leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly & Co., Spectrum Pharmaceuticals and The Medicines Company. Please visit www.captisol.com for more information on Captisol or www.ligand.com for more information on Ligand.

Follow Ligand on Twitter @Ligand_LGND.

Forward-Looking Statements

This news release contains certain forward-looking statements by Ligand that involve risks and uncertainties, and reflect Ligand’s judgment as of the date of this release. These statements include those related to the permitted purchase of Ligand common stock by BVF, and the future value of Ligand common stock. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Ligand’s stock price. Additional information concerning these and other risk factors affecting Ligand’s business can be found in prior press releases available via www.ligand.com as well as in Ligand’s public periodic filings with the Securities and Exchange Commission at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Sprint and Clearwire (CLWR) Agree to Increased Acquisition Offer

SPRINT AND CLEARWIRE AGREE TO INCREASED ACQUISITION OFFER

• Increased Offer to $5.00 Per Share Represents Significant Premium to Unaffected Clearwire Trading Price and DISH Network Tender Offer
• Group of Significant Minority Stockholders Agree to Vote in Favor of Sprint Transaction
• Offer Provides Clearwire Stockholders with Certain and Attractive Value

Sprint (NYSE:S) and Clearwire (NASDAQ:CLWR) today announced that they have agreed to amend Sprint’s agreement to acquire the approximately 50 percent of Clearwire it does not currently own (the “minority stake”) for $5.00 per share, valuing Clearwire at approximately $14 billion, or about $0.30 per MHZ-pop. This increased offer represents a 47 percent premium to Sprint’s previous offer of $3.40 per share announced on May 21, 2013 and a 285 percent premium to Clearwire’s closing share price on Oct. 10, 2012, the day before the Sprint-SoftBank discussions were first confirmed in the marketplace and Clearwire was speculated to be a part of that transaction. This offer also represents a 14 percent premium to the $4.40 per share DISH tender offer.

Sprint has received commitments from a group of significant Clearwire stockholders, including Mount Kellett Capital Management LP, Glenview Capital Management LLC, Chesapeake Partners Management Co., Inc. and Highside Capital Management LP, which collectively own approximately 9 percent of Clearwire’s voting shares, to vote their shares in support of the transaction. These stockholders have also agreed to sell their shares to Sprint in the event the transaction does not close.

Together with the voting commitments previously received from Comcast Corp., Intel Corp and Bright House Networks LLC, who collectively own approximately 13 percent of Clearwire’s voting shares, and Clearwire’s directors and officers, stockholders owning approximately 45 percent of the Clearwire voting shares not affiliated with Sprint, have now agreed to vote their shares in support of the transaction. Sprint expects a majority of the non-Sprint stockholders to support the Clearwire merger based on these agreements and the votes of shareholders with both Sprint and Clearwire shareholdings who have already voted in favor of the Sprint SoftBank transaction.

In addition to the increased price per share, the companies have further amended the merger agreement that was previously entered into. Specifically, among other things, in certain circumstances where the transaction between Sprint and Clearwire terminates, Clearwire will be required to pay a termination fee of $115 million, or 3 percent of the equity value of the minority stake. In the event the transaction is not completed, Clearwire has agreed to hold its annual shareholder meeting as expeditiously as possible and if the transaction is not completed under certain circumstances, Clearwire has agreed to waive the current standstill provision in the Equityholders’ Agreement between Sprint, Clearwire, and the company’s strategic investors. That standstill provision was originally set to expire on November 28, 2013.

The revised offer demonstrates Sprint’s commitment to closing the Clearwire transaction and improving its competitive position in the U.S. wireless industry. Sprint is uniquely positioned to leverage Clearwire’s 2.5 GHz spectrum assets. Sprint’s Network Vision architecture should allow for better strategic alignment and the full utilization and integration of Clearwire’s complementary 2.5 GHz spectrum assets, while achieving operational efficiencies and improved service for customers as the spectrum and network is migrated to 4G LTE standards.

Sprint’s proposal provides a clear path forward for Clearwire and the merger provides attractive value for shareholders of both companies.

The transaction is subject to customary closing conditions, including regulatory approvals and the approval of Clearwire’s stockholders, including the approval of a majority of Clearwire stockholders not affiliated with Sprint or SoftBank. The closing of the transaction is also contingent on the consummation of Sprint’s previously announced transaction with SoftBank. SoftBank has consented to the amendment.

About Sprint Nextel

Sprint Nextel offers a comprehensive range of wireless and wireline communications services bringing the freedom of mobility to consumers, businesses and government users. Sprint Nextel served more than 55 million customers at the end of the first quarter of 2013 and is widely recognized for developing, engineering and deploying innovative technologies, including the first wireless 4G service from a national carrier in the United States; offering industry-leading mobile data services, leading prepaid brands including Virgin Mobile USA, Boost Mobile, and Assurance Wireless; instant national and international push-to-talk capabilities; and a global Tier 1 Internet backbone. The American Customer Satisfaction Index rated Sprint No. 1 among all national carriers in customer satisfaction and most improved, across all 47 industries, during the last four years. Newsweek ranked Sprint No. 3 in both its 2011 and 2012 Green Rankings, listing it as one of the nation’s greenest companies, the highest of any telecommunications company. You can learn more and visit Sprint at www.sprint.com or www.facebook.com/sprint and www.twitter.com/sprint.

About Clearwire

Clearwire Corporation (Nasdaq:CLWR), through its operating subsidiaries, is a leading provider of 4G wireless broadband services offering services in areas of the U.S. where more than 130 million people live. The company holds the deepest portfolio of wireless spectrum available for data services in the U.S. Clearwire serves retail customers through its own CLEAR® brand as well as through wholesale relationships with some of the leading companies in the retail, technology and telecommunications industries, including Sprint and NetZero. The company is constructing a next-generation 4G LTE Advanced-ready network to address the capacity needs of the market, and is also working closely with the Global TDD-LTE Initiative to further the TDD-LTE ecosystem. Clearwire is headquartered in Bellevue, Wash. Additional information is available at http://www.clearwire.com.

Cautionary Statement Regarding Forward-Looking Statements

This document includes “forward-looking statements” within the meaning of the securities laws. The words “may,” “could,” “should,” “estimate,” “project,” “forecast,” intend,” “expect,” “anticipate,” “believe,” “target,” “plan,” “providing guidance” and similar expressions are intended to identify information that is not historical in nature. This document contains forward-looking statements relating to the proposed Merger between Sprint and Clearwire pursuant to the Merger Agreement and the related transactions (collectively, the “transaction”). All statements, other than historical facts, including statements regarding the expected timing of the closing of the transaction; the ability of the parties to complete the transaction considering the various closing conditions; the expected benefits and synergies of the transaction; the competitive ability and position of Sprint and Clearwire; and any assumptions underlying any of the foregoing, are forward-looking statements. Such statements are based upon current plans, estimates and expectations that are subject to risks, uncertainties and assumptions. The inclusion of such statements should not be regarded as a representation that such plans, estimates or expectations will be achieved. You should not place undue reliance on such statements. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include, among others, (i) any conditions imposed in connection with the transaction, (ii) approval of the transaction by Clearwire stockholders, (iii) the satisfaction of various other conditions to the closing of the transaction contemplated by the Merger Agreement, (iv) legal proceedings that may be initiated related to the transaction, and (v) other factors discussed in Clearwire’s and Sprint’s Annual Reports on Form 10-K for their respective fiscal years ended December 31, 2012, their other respective filings with the U.S. Securities and Exchange Commission (the “SEC”) and the proxy statement and other materials that have been or will be filed with the SEC by Clearwire in connection with the transaction. There can be no assurance that the transaction will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the transaction will be realized. None of Sprint, Clearwire or Collie Acquisition Corp. undertakes any obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Additional Information and Where to Find It

In connection with the transaction, Sprint and Clearwire have filed a Rule 13e-3 Transaction Statement and Clearwire has filed a definitive proxy statement with the SEC. The definitive proxy statement has been mailed to the Clearwire’s stockholders. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER RELEVANT MATERIALS BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT CLEARWIRE AND THE TRANSACTION. Investors and security holders may obtain free copies of these documents and other documents filed with the SEC at the SEC’s web site at www.sec.gov. In addition, the documents filed by Clearwire with the SEC may be obtained free of charge by contacting Clearwire at Clearwire, Attn: Investor Relations, (425) 505-6494. Clearwire’s filings with the SEC are also available on its website at www.clearwire.com.

Participants in the Solicitation

Clearwire and its officers and directors and Sprint and its officers and directors may be deemed to be participants in the solicitation of proxies from Clearwire stockholders with respect to the transaction. Information about Clearwire officers and directors and their ownership of Clearwire common shares is set forth in the definitive proxy statement for Clearwire’s Special Meeting of Stockholders, which was filed with the SEC on April 23, 2013. Information about Sprint’s officers and directors is set forth in Sprint’s Annual Report on Form 10-K for the year ended December 31, 2012, which was filed with the SEC on February 28, 2013. Investors and security holders may obtain more detailed information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the transaction by reading the definitive proxy statements regarding the transaction, which was filed by Clearwire with the SEC.

(OTIV) Announces Results of Markman Hearing in Patent Infringement Suit Against T-Mobile

ROSH PINA, Israel, June 20, 2013 (GLOBE NEWSWIRE) — On Track Innovations Ltd. (“OTI“) (Nasdaq:OTIV) announced that it received today the favorable decision on claim construction in the patent infringement lawsuit alleging that Near Field Communication (NFC) enabled phones sold by T-Mobile USA, Inc. infringe OTI’s U.S. Patent No. 6,045,043 (the “‘043 patent”). The Honorable Judge Alison J. Nathan’s “adopt[ed] [OTI’s] proposed constructions of all four disputed terms.”

The lawsuit is pending in the United States District Court for the Southern District of New York and was filed in March, 2012. Today’s decision followed two days of proceedings last month, including a technology tutorial followed by a claim construction argument before the Court. The Court considered the meaning of certain technical terminology used in the ‘043 patent. A copy of today’s decision can be found here http://otiglobal.com/Press_Releases.

“Today’s decision validates OTI’s intellectual property and strongly supports our view that the ‘043 patent is fundamental to every NFC-enabled phone,” said OTI’s CEO, Ofer Tziperman. The ‘043 patent is part of OTI’s extensive intellectual property portfolio, including over two dozen issued patents and pending patent applications in the US and numerous more around the world encompassing product applications, software platforms, system and product architecture, product concepts and more in the fields of NFC, contactless payments, secure ID, petroleum and parking solutions.

OTI is a pioneer in the contactless payment market and supported MasterCard® and Visa®, among others, in the creation and implementation of contactless transaction processing and payment solutions. OTI provides NFC devices and reader solutions including the COPNI (Contactless Payment and NFC Insert) device, which adds NFC capability to existing (non-NFC) mobile phones.

About OTI

On Track Innovations Ltd. (“OTI”) is a leader in contactless and NFC applications based on its extensive patent and IP portfolio. OTI’s field-proven innovations have been deployed around the world to address NFC payment solutions, national electronic ID systems, petroleum payment and management, cashless parking fee collection systems and mass transit ticketing. OTI markets and supports its solutions through a global network of regional offices and alliances. Visit the website: www.otiglobal.com.

Safe Harbor for Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on OTI’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of OTI could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained in this press release are subject to other risks and uncertainties, including those discussed in the “Risk Factors” section and elsewhere in OTI’s annual report on Form 20-F for the year ended December 31, 2012 and in subsequent filings with the Securities and Exchange Commission. Except as otherwise required by law, OTI disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

CONTACT: OTI Contact:
         Galit Mendelson
         VP, Corporate Relations
         732 429 1900 ext. 111
         galit@otiglobal.com

(LPHI) CEO Files Whistleblower Complaint for Naked Short Selling, Market Manip

Brian Pardo, CEO of Life Partners Holdings, Inc. (“Life Partners”) (Nasdaq GS: LPHI), parent company of Life Partners, Inc., announced today that an independent investigation has uncovered substantial evidence of coordinated market manipulation and naked short selling of Life Partners’s stock in and around September 26, 2012. As a result of this investigation, he has filed a whistleblower complaint with the U.S. Securities and Exchange Commission against a number of persons and entities suspected of illegal short-selling activities. Pardo has filed the complaint on Life Partners’ behalf since SEC regulations require that only individual, natural persons can file such complaints.

The investigation was conducted by former SEC Senior Counsel and noted whistleblower, Gary Aguirre. Mr. Aguirre, who has testified before the Senate regarding how politically influential individuals and Wall Street firms taint the SEC’s enforcement decisions, has been an outspoken critic against abusive short selling and the lack of SEC enforcement against this illegal activity.

Naked short selling is the practice of short selling a company’s stock without first borrowing the security as required in a legitimate short sale. Because shares are not borrowed, naked short selling is similar to counterfeiting as it can make a company appear to have many more stockholders selling shares than are actually being sold. In 2008, the SEC banned “abusive naked short selling” as a method of driving down share prices. This abusive tactic is used, often in conjunction with the dissemination of negative rumors, to drive down a company’s stock price for the profit of the short sellers. It can also result in massive job losses, substantial financial losses to legitimate shareholders and ultimately the destruction of companies.

In his complaint, Pardo describes Life Partners as a microcap stock with 18.4 million issued shares. Pardo holds more of than half of these shares, which are unavailable for trading. Accordingly, Life Partners has less than 9.2 million shares available for trading and usually less than one million shares are available for borrowing. In the 12-month period before September 2012, Life Partners’s stock had an average daily trading volume of 112,000 shares.

The complaint demonstrates that market participants, identifiable through blue sheets, manipulated the price of Life Partners’ stock on September 26 and 27, 2012, through massive naked short selling in violation of the SEC’s Regulation SHO. A public announcement of highly favorable news after the market close on September 25, 2012 – Life Partners success in a legal action – generated strong upward pressure on the stock price when the market opened on September 26. Over the next two days, approximately 15.2 million shares traded. The upside pressure was resisted by aggressive short selling at the bid from the market’s opening on September 26 and continued unabated until a price reversal on September 27. Over these two days, at least 2.16 million shares were shorted at the bid, a type of trade that fits within no exception to the legal borrow requirements. Altogether, a staggering 6.96 million shares were sold short over the two days. At the time, there were at most 1 million shares available for borrowing and perhaps none. Major violations of Reg SHO were a virtual certainty.

The complaint further demonstrates other violations, such as the requirement that short sellers must deliver by the settlement date. If 6.96 million shares were properly borrowed, they would have resulted in an increase of shares on loan. But by October 3, 2012, the day after the settlement date for the trades on September 27, the shares on loan had only increased by 27,600 shares. If the shorts were not covered by the settlement date, they were naked and in violation of Reg SHO.

Under the whistleblower provisions of the Dodd-Frank law, a reward may be issued if the SEC is successful in collecting fines against the violators. Mr. Pardo has assigned any such reward to the Life Partners Holdings, Inc. and no officers or directors would receive any part of such an award.

Life Partners Holdings CEO Brian Pardo commented, “It is a tragedy to realize that there are well-known financial entities that intentionally try to destroy companies with these abusive tactics, without any regard for the lives of the workers and the investors they ruin. The original purpose of our financial markets was to bring capital to companies so they could grow and, in turn, contribute to the growth of our whole economy. This small group has hijacked our financial markets for their own gain. I just hope that the SEC will use the clear evidence we have provided to them to bring those who are working against our economy to justice. In my view, naked short selling is a form of financial terrorism.”

Pardo further suggests in the complaint that FINRA settlements with UBS and Credit Suisse speak to the enormous magnitude of naked short selling. He points to the recent SEC settlement with the Chicago Board Options Exchange, which shows how an SRO was compromised by those who engage in naked short selling. An investigation of the allegations in the whistleblower complaint filed by Mr. Pardo promises to provide the SEC with an opportunity to contain naked short selling while affording better insights into how naked shorting is being used to afflict small public companies.

Life Partners is the world’s oldest and one of the most active companies in the United States engaged in the secondary market for life insurance, commonly called “life settlements.” Since its incorporation in 1991, Life Partners has completed over 149,000 transactions for its worldwide client base of over 29,000 high net worth individuals and institutions in connection with the purchase of over 6,500 policies totaling over $3 billion in face value.

Visit our website at: www.lphi.com.

Safe Harbor – This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The statements in this news release that are not historical statements, including statements regarding the basis, prosecution or outcome of the claims in the whistleblower complaint, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks and uncertainties, many of which are beyond our control, that could cause actual results to differ materially from such statements. For information concerning these risks and uncertainties, see our most recent Form 10-K. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

(NKTR) Presents Positive Data from Human Abuse Liability Study on Opioid to Treat Chronic Pain

NKTR-181 rates similar to placebo on “drug liking” and “feeling high” scores at all doses studied and differentiates from the widely abused drug oxycodone with high statistical significance (p<0.0001)

SAN DIEGO, June 19, 2013 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced positive top-line results from a human abuse liability (HAL) study for NKTR-181, a first-in-class, opioid analgesic molecule with a slow rate of entry into the brain.  This slow rate of entry is designed to reduce the euphoria that can lead to the abuse of and addiction to current opioid analgesics.¹ In the study data being presented today, NKTR-181 was rated similar to placebo in “drug liking” and “feeling high” scores and had highly statistically significant lower “drug liking” scores and reduced “feeling high” scores as compared to oxycodone at all doses tested (p<0.0001).

Prescription opioids are critical in the management of moderate-to-severe chronic pain.  However, the abuse and misuse of these opioids have led to a serious public health crisis.   HAL studies are clinical studies that assess the relative abuse potential of a medicine.  These studies are conducted in a non-dependent, recreational drug abuser population and are designed to predict how probable it is that a particular medicine will be attractive to abusers (i.e., “liked”).  The primary endpoint for the NKTR-181 HAL study was drug-liking measured on a bi-polar visual analogue scale (VAS).  This endpoint is known to correlate most directly with a drug’s potential for abuse.²

“It is clear that there is a pressing societal need for better and safer analgesics,” said Dr. Lynn Webster, President of the American Academy of Pain Medicine and lead investigator for the study at CRI Lifetree. “We know that speed of entry into the brain is important in abuse.  When we look at the critical period following dosing when the commonly abused drug oxycodone reaches maximum liking, NKTR-181 was not distinguished from placebo with respect to both drug-liking and feeling high.  These are two of the most important metrics that help us understand the abuse potential of a medicine.  Importantly, NKTR-181 was dosed as an oral liquid, which underscores that its less rewarding properties are inherent to this NCE and independent of any abuse-deterrent formulation.  These data, along with previous efficacy data, suggest NKTR-181 may be a major advance towards safer opioid therapy for the treatment of moderate to severe chronic pain.”

The HAL study compared drug liking between each treatment group (oxycodone 40 mg, Placebo, and NKTR-181 100 mg, 200 mg, and 400 mg).  On the bipolar VAS scale (0-100), a score of 50 indicates that the subject “neither likes nor dislikes” the drug.  In the study, 40 mg of oxycodone oral solution resulted in a maximum mean drug liking score of 85, indicating a “strong liking” for the effects of oxycodone.  The oxycodone liking score was significantly different from placebo as early as 15 minutes after dosing and peaked at 60 minutes. In the placebo arm, the maximum mean drug liking score was 50, indicating that the subjects neither liked nor disliked the effects.  NKTR-181 dosing was similar to placebo with maximum mean drug liking VAS scores of 58, 58 and 63 for 100 mg, 200 mg and 400 mg, respectively.

“The data from this study are remarkable and clearly demonstrate that drug abusers could not discriminate NKTR-181 from placebo at doses that we know produced analgesia in the validated pain models from our Phase 1 studies,” said Robert Medve MD, SVP and Chief Medical Officer of Nektar Therapeutics. “These data suggest that NKTR-181 could change the way we think about opioids and how we treat patients with chronic pain.”

Additional Study Results

• Assessment of “Feeling High”

All oral doses of NKTR-181 scored similar to placebo in a Drug Effects Questionnaire (DEQ) assessing the treatment’s effect on how “high” the subject felt (on a scale of 0 (not at all) to 100 (extremely)).  Oxycodone oral solution resulted in a maximum mean DEQ score of 81.   NKTR-181 maximum mean DEQ scores were 14, 14 and 23 for 100 mg, 200 mg tablet and 400 mg, respectively, with p-values < 0.0001 as compared to oxycodone.  Placebo achieved a maximum mean DEQ score of 9.

• Assessment of “Sleepiness”

Sedation was measured using a DEQ assessment of sleepiness (on a scale of 0 (not at all) to 100 (extremely).  All doses of NKTR-181 scored lower on sleepiness when compared to oxycodone.  The maximum mean DEQ sleepiness score for oxycodone was 44 as compared to the maximum mean DEQ scores for NKTR-181 100 mg, 200 mg and 400 mg of 10, 9, and 18, respectively (p<0.0001).

Study Design

The randomized, double-blind, placebo- and active-controlled, 5-way crossover trial, compared the effects of three doses of NKTR-181 oral solution (100 mg, 200 mg, and 400 mg), to the effects of 40 mg of oxycodone oral solution and placebo.  Participants were healthy adults (N=42) who were not currently physically opioid-dependent but had used opioids to attain non-medical effects on at least 10 occasions during the past year and at least once in the 12 weeks before the study.  Study participants sequentially received the five treatments, administered in a randomized, double-blinded fashion, with each treatment separated by a washout period.  The study also utilized a Williams Square cross-over design, which uses a series of randomized sequences for each individual subject.

About NKTR-181

NKTR-181 is currently being evaluated in Phase 2 development as a twice-daily oral tablet to treat chronic pain.  The NKTR-181 Phase 2 study is a double-blind, placebo-controlled, randomized withdrawal study design evaluating the investigational drug candidate in patients with moderate to severe chronic pain from osteoarthritis of the knee.  Approximately 200 patients will be randomized to receive either NKTR-181 or placebo in the study.

NKTR-181 is an NCE (new chemical entity) which was created using Nektar’s proprietary small molecule polymer conjugate technology and its potential differentiating properties are inherent to its molecular design.  In June of 2012, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to NKTR-181 for the treatment of moderate to chronic pain.

A Phase 1 clinical program for NKTR-181 has been completed in approximately 160 healthy volunteers.  These studies showed that NKTR-181 produced sustained and dose-dependent analgesic responses with twice-daily dosing over a period of 8 days.  These studies also measured the contraction of pupils over time following dosing with NKTR-181 and the data confirmed that NKTR-181 has a slow rate of entry into the CNS (central nervous system).  This slow rate of entry is designed to reduce the euphoria that can lead to abuse and addiction to current opioid analgesics.¹

Analyst Call to be Held 10:00 AM Pacific Time/1:00 PM Eastern Time on Wednesday, June 19, 2013

The company will be hosting a call to discuss these data with analysts and investors at 10:00 AM Pacific time/1:00 PM Eastern time today.  Hosting the call will be Howard Robin, President and CEO of Nektar, and Robert Medve, MD, Chief Medical Officer.  Joining company management will be Sidney H. Schnoll, MD, PhD of PinneyAssociates, an internationally recognized expert in addiction and pain management.

A live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. To access the conference call live, follow these instructions:

The webcast replay of the conference call will be available through June 24, 2013.

About Opioids and Pain Management

Pain is one of the most common reasons people seek medical treatment.¹ The American Pain Society estimates that 36 percent of the U.S. population, or 105 million people, suffer from chronic pain in the United States. Chronic pain conditions, such as osteoarthritis, back pain and cancer pain, affect at least 126 million adults in the U.S. annually and contribute to over $100 billion a year in direct healthcare expenditures and lost work time.³ Opioids are considered the most effective therapeutic option for pain, with sales exceeding over $10 billion a year in the U.S. alone.^4,5 However, opioids can cause serious side effects such as respiratory depression and sedation and have the potential for addiction, abuse and misuse. In 2010, the Centers for Disease Control and Prevention (CDC) reported that emergency room visits for non-medical use of opioid analgesics increased 111 percent over a five-year period.⁶

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia.

Nektar’s technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB’s Cimzia® for Crohn’s disease and rheumatoid arthritis, Roche’s PEGASYS® for hepatitis C and Amgen’s Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar’s proprietary technology platform include Baxter’s BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential for NKTR-181 as a potentially new opioid therapy with reduced abuse potential, and the value and potential of our technology and drug candidates in our research and development pipeline.  Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) NKTR-181 is in the earlier stages of clinical development and could fail at any time due to numerous unpredictable and significant risks related to safety, efficacy and other important findings that can negatively impact clinical development; (ii) although we have conducted various experiments using laboratory and home-based chemistry techniques that have so far been unable to convert NKTR-181 into a rapid-acting, more abusable opioid, it is possible that an alternative chemistry technique or process may be discovered in the future that would enable the conversion of NKTR-181 into a more abusable opioid; (iii) the statements regarding the therapeutic potential of NKTR-181 as an opioid analgesic are based on preclinical data and data from Phase 1 clinical studies and results from future clinical studies, including the ongoing placebo-controlled Phase 2 efficacy clinical study for NKTR-181, may fail to confirm these earlier analgesic findings; (iv) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar’s technology platform to potential new drug candidates such as NKTR-181 is therefore very uncertain and unpredictable and could unexpectedly fail at any time; (v) patents may not issue from our patent applications for NKTR-181, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vi) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2013. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

(1) Hyman, Steven E., Harvard Review of Psychiatry. 2(1):43-46, May/June 1994.

(2) Source: January 2013 Guidance for Industry: Abuse-Deterrent Opioids – Evaluation and Labeling – Draft Guidance distributed by the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)

(3) 2011 National Academy of Sciences. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research, 2010 Decision Resources, and Harstall, C. How prevalent is chronic pain? Pain Clinical Updates X, 1—4 (2003).

(4) IMS, NSP, NPA and Defined Health 2010 Estimates.

(5) Melnikova, I, Pain Market, Nature Reviews Drug Discovery, Volume 9, 589-90 (August 2010).

(6) Morbidity and Mortality Weekly Report (MMWR), Emergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs — United States, 2004—2008, 59(23);705-709 (June 2010).

(MFRI) Announces Over $30 Million in New Major Orders

NILES, IL — (Marketwired) — 06/19/13 — (NASDAQ: MFRI) In press releases dated November 26, 2012 and February 5, 2013, the Company described major orders received by Perma Pipe Saudi Arabia in support of large-scale construction projects expanding the Haram Grand Mosque in Mecca and the King Abdul-Aziz International Airport in Jeddah. Those orders totaled nearly $50 million. Since then, the Company has received $55 million in new global orders, of which $25 million was reported in the first quarter backlog. The new global orders include:

• several contracts exceeding $19 million for offshore pre-insulated piping and sub-sea equipment to support the construction of flow lines in the Gulf of Mexico,
• additions to the two landmark Saudi projects, and
• projects in Qatar, Abu Dhabi and other Gulf Cooperation Council (“GCC”) markets awarded to our middle eastern subsidiaries.

Delivery of the new GCC orders has begun and we expect to commence production of the $19 million offshore orders in the fourth quarter of this year and complete all deliveries by mid-2014.

Fati Elgendy, President of Perma-Pipe, Inc., said, “We are honored to participate in the efforts to enhance the Kingdom of Saudi Arabia’s capacity to accommodate religious tourism. These orders expand the chilled water infrastructure at the Holy Haram and provide insulated piping for district cooling plants as well as other utility infrastructure at the Jeddah airport. Additionally, Perma Pipe’s subsidiary in the United Arab Emirates received several orders to provide piping for the district cooling utility infrastructure for Abu Dhabi Airport and at Qatar’s flagship planned community named Lusail City. We believe these orders establish our subsidiaries in the GCC as the undisputed market leader and are another strong endorsement of our resolve to serve the high growth markets of the GCC.”

Bradley Mautner, President and CEO, added, “The success of Perma-Pipe in continuing to secure these significant orders demonstrates our strong technical and commercial capabilities required for sophisticated insulated piping systems. Our ability to meet ever-changing customer requirements and willingness to go where needed differentiate us from others who serve these markets. I am particularly proud of Perma Pipe’s proactive attitude as they address customer needs wherever they may arise around the globe.”

MFRI, Inc. is a multi-line company engaged in the following businesses: pre-insulated specialty piping systems for oil and gas gathering, district heating and cooling and other applications; custom-designed industrial filtration products to remove particulates from dry gas streams; and installation of heating, ventilation and air conditioning for large buildings. For more information visit the Company’s website www.mfri.com or contact the Company directly.

Statements and other information contained in this announcement which can be identified by the use of forward-looking terminology such as “anticipate,” “may,” “will,” “expect,” “continue,” “remain,” “intend,” “aim,” “should,” “prospects,” “could,” “position,” “future,” “potential,” “believes,” “plans,” “likely,” ” seems,” and “probable,” or the negative thereof or other variations thereon or comparable terminology, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 as amended and are subject to the safe harbors created thereby. These statements should be considered as subject to the many risks and uncertainties that exist in the Company’s operations and business environment. Such risks and uncertainties include, but are not limited to, economic conditions, market demand and pricing, competitive and cost factors, raw material availability and prices, global interest rates, currency exchange rates, labor relations and other risk factors.

Amtech (ASYS) Obtains Second High-Efficiency N-Type Solar Customer

TEMPE, Ariz., June 19, 2013 /PRNewswire/ — Amtech Systems, Inc. (NASDAQ: ASYS), a global supplier of production and automation systems and related supplies for the manufacture of solar cells, semiconductors, and sapphire and silicon wafers, today announced its solar subsidiary, Tempress Systems, received a multi-million dollar order (in the low teens) for its advanced diffusion and PECVD equipment to be used in Nexolon USA’s facility located in San Antonio, Texas. The order is for 100MW and is the first phase of a planned 200MW turnkey project executed by the n-PASHA Alliance for Nexolon. Shipment is expected in the first half of fiscal 2014.

The n-PASHA Alliance members consist of Tempress Systems, ECN (Energy Research Centre of The Netherlands), and RENA GmbH. The Alliance was established in 2012 to more effectively offer the n-PASHA technology, an n-type bi-facial cell concept developed by ECN, which yields high cell efficiencies at a competitive cost level to the solar industry. The n-PASHA cells used for bi-facial modules generate electricity from light coming through both the front and rear side of the panel positioning the solar field to generate 10-20% more power at no additional cost. Additionally, the n-type modules do not suffer from LID (light induced degradation) compared to power loss of typically several percentage points for commonly used p-type modules.

Mr. Fokko Pentinga, CEO of Amtech Systems, Inc., commented: “We have found that through continued research and development and advancement of the n-PASHA technology we can support a distinguishable next generation high efficiency solar cell structure solution at an attractive cost of ownership.  Obtaining the second customer for this n-type technology, as well as a production order for our new PECVD systems, is a great milestone for Amtech, underscoring that Amtech is on the right technology path as the solar market progresses towards higher value solutions. At Tempress, with our industry-leading Alliance partners, we are well-positioned to participate and capitalize on the solar industry’s next technology buying cycle, and we believe the n-type cell will be the choice of many customers in the coming years. We look forward to working with Nexolon in San Antonio, Texas, a future solar hub in the USA, on this exciting project.”

For more information, please check http://www.prnewswire.com/news-releases/n-pasha-alliance-awarded-100-mw-n-type-technology-and-equipment-order-for-nexolon-turnkey-project-in-usa-212104421.html

About Amtech Systems, Inc.

Amtech Systems, Inc. manufactures capital equipment, including silicon wafer handling automation, thermal processing and ion implant equipment and related consumables used in fabricating solar cells, LED and semiconductor devices. Semiconductors, or semiconductor chips, are fabricated on silicon wafer substrates, sliced from ingots, and are part of the circuitry, or electronic components, of many products including solar cells, computers, telecommunications devices, automotive products, consumer goods, and industrial automation and control systems. The Company’s wafer handling, thermal processing and consumable products currently address the diffusion, oxidation, and deposition steps used in the fabrication of solar cells, LEDs, semiconductors, MEMS and the polishing of newly sliced silicon wafers.

Cautionary Note Regarding Forward-Looking Statements

This press release should be read in conjunction with our consolidated financial statements and the related notes and Management’s Discussion and Analysis included in Amtech Systems, Inc.’s filing on Form 10-Q or Form 10-K for the fiscal periods referred to above. Certain information contained in this press release is forward-looking in nature. All statements in this press release, or made by management of Amtech Systems, Inc. and its subsidiaries (“the Company” or “Amtech”), other than statements of historical fact, are hereby identified as “forward-looking statements” (as such term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “would,” “expects,” “plans,” “anticipates,” “intends,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology.  Examples of forward-looking statements include statements regarding Amtech’s future financial results, operating results, business strategies, projected costs, products under development, competitive positions and plans and objectives of the Company and its management for future operations.

We cannot guarantee that any forward-looking statement will be realized, although we believe that the expectations reflected in the forward-looking statements are reasonable. Achievement of future results is subject to risks, uncertainties and potentially inaccurate assumptions. The Form 10-K that we filed with the Securities and Exchange Commission for the year-ended September 30, 2012 listed various important factors that could affect Amtech’s future operating results and financial condition and could cause actual results to differ materially from historical results and expectations based on forward-looking statements made in this document or elsewhere by Amtech or on its behalf.  These factors can be found under the heading “Risk Factors” in the Form 10-K and investors should refer to them.  Because it is not possible to predict or identify all such factors, any such list cannot be considered a complete set of all potential risks or uncertainties.  Except as required by law, we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

AV Homes (AVHI) Announces $135 Million Equity Investment by TPG

Investment Will Accelerate Implementation of Strategic Plan

SCOTTSDALE, Ariz., June 19, 2013 (GLOBE NEWSWIRE) — AV Homes, Inc. (Nasdaq:AVHI), a developer and builder of active adult and conventional home communities in Arizona and Florida, today announced that TPG, a leading global private investment firm, has agreed to make a $135 million investment in the Company at a price of $14.65 per share, which represents a 9.6% premium to the 30-day trailing average closing price of AV Homes’ common stock. AV Homes will use the proceeds to accelerate the implementation of its strategic growth plan in its existing and new high-potential housing markets. In addition the Company has adopted a shareholder rights plan effective today designed to protect its net operating loss assets from the application of Section 382 of the Internal Revenue Code.

Since 2011, AV Homes has strategically re-engineered the Company to position it to benefit from the recovery of the homebuilding industry. It reduced overhead, launched initiatives to improve internal processes, invested in a new scalable IT platform, and developed a strategic plan to guide its growth.

Roger A. Cregg, AV Homes’ President and Chief Executive Officer, said the investment will allow the Company to pursue new investment opportunities in its core markets in line with the Company’s long-term strategy. “We’re delighted that a renowned global private investment firm such as TPG has confidence in our vision, and in our ability to execute that vision, as the housing industry continues its recovery. It’s an exciting time for AV Homes and I am confident that the implementation of our plans will drive growth and deliver long-term value to our shareholders,” Cregg said.

AV Homes currently operates in the Phoenix, Arizona and Central and South Florida markets. The Company’s primary operations are focused on the development of active adult communities designed for people 55+ through its Vitalia brand, and serving the housing needs of first-time and move-up homebuyers through its Joseph Carl Homes brand.

Kelvin Davis, senior partner at TPG, said AV Homes has established a strong platform for future growth. “AV Homes has assembled a strong management team with deep industry experience. The Company is well-positioned to participate in the on-going recovery of the housing market, with real estate assets located in two healthy and growing Sunbelt markets,” Davis said.

Key Investment Terms

The investment by TPG has been approved by AV Homes’ Board of Directors and it is anticipated that funding will take place by Thursday, June 20, 2013. The key terms of the investment are as follows:

• TPG will make a $135 million equity investment in AV Homes at $14.65 per share, a 9.6% premium to the 30-day trailing average closing price of AV Homes’ common stock.
• At the closing of the transaction, the Company will issue approximately 2.6 million shares, or approximately $37.5 million, of common stock, representing approximately 19.9% of the Company’s outstanding common stock, and approximately 0.7 million shares, with an initial liquidation value of $97.5 million, of newly created Series A Contingent Convertible Cumulative Redeemable Preferred Stock (the “Series A Convertible Preferred Stock”).
• TPG’s ownership in the Company will be approximately 41.9% on an as-converted basis at the closing of the transaction.
• The Series A Convertible Preferred Stock is convertible on a ten-for-one basis upon stockholder approval, in accordance with NASDAQ rules. AV Homes has agreed to hold a meeting of its stockholders within 90 days following the closing date for stockholders to vote on the conversion of the preferred stock into common stock. Two of the Company’s largest stockholders, ODAV LLC and JEN Partners, LLC, representing 24.2% of the outstanding common stock of the Company, have both disclosed to the Company their intention to vote in favor of the conversion.
• The Series A Convertible Preferred Stock will accrue increasing quarterly dividends beginning in six months, if the preferred shares remain outstanding.
• TPG will have two of eight Board seats at closing, increasing to four of ten Board seats upon receipt of stockholder approval. In addition, TPG will have the right to have two directors appointed to the compensation committee and a newly created finance committee, both of which will have five members, and will have the right to have one director appointed to each other Board committee. TPG’s Board and committee representation will decrease in the event its ownership percentage decreases below certain specified levels.
• TPG will have consent rights for certain major decisions of the Company as long as it maintains at least 10% ownership of the Company’s common stock on an as-converted basis and at least 25% of the common stock it will hold on an as-converted basis at closing of the transaction.

As noted above, TPG will acquire a 41.9% ownership interest in the Company following the transaction. Because of the Company’s net operating loss position, it has generated a significant net operating loss (NOL) carry forward for federal income tax purposes. The Company’s ability to use its NOLs can be negatively impacted if there is an “ownership change” as defined under Internal Revenue Code Section 382. In general, this would occur if certain ownership changes related to the Company’s stock that are held by 5% or greater stockholders exceeds 50% measured over a rolling three year period. Therefore, the Company has also adopted a shareholder rights plan effective today that is designed to protect the Company’s valuable NOLs from the application of Section 382, which can restrict the use of NOLs following a change of ownership. Under the plan, when a person or group has obtained beneficial ownership of 4.9% or more of the Company’s common stock, or an existing holder with greater than 4.9% ownership acquires more shares of the Company’s common stock, there would be a triggering event causing significant dilution in the economic interest and voting power of such person or group. The Company’s Board of Directors, acting through its newly formed Finance Committee, has the discretion to exempt an acquisition of common stock from the provisions of the rights plan. The details of the operation of the rights plan, and certain exemptions from the rights plan that the Board has approved with respect to TPG, can be found in the Company’s Current Report on Form 8-K, which the Company expects to file this week.

Conference Call

AV Homes will hold a conference call and webcast on Wednesday, June 19, 2013 at 4:30 pm (EDT) to discuss this transaction. The conference call can be accessed live over the telephone by dialing (877) 643-7158 or for international callers by dialing (914) 495-8565; please dial-in 10 minutes before the start of the call. A replay will be available on June 19, 2013 at 7:30 pm and can be accessed by dialing (855) 859-2056 or for international callers by dialing (404) 537-3406; the conference ID is 98949722. The replay will be available until June 26, 2013.

In order to access the live webcast, participants may go to the Investors section of AV Homes website at www.avhomesinc.com and click on the webcast link that will be made available. A replay will be available shortly after the original webcast.

Advisors

Moelis & Company LLC is acting as financial advisor to AV Homes, and Faegre Baker Daniels LLP is acting as legal counsel for AV Homes in connection with the TPG transaction. Ropes & Gray LLP is acting as TPG’s legal counsel.

About AV Homes

AV Homes, Inc. is engaged in homebuilding, community development and land sales in Florida and Arizona. Its principal operations are conducted near Orlando, Florida and in the Phoenix, Arizona markets. The Company serves active adults 55+ with its Vitalia brand and also builds communities for people of all ages under its Joseph Carl Homes brand. AV Homes common shares trade on NASDAQ under the symbol AVHI. For more information visit www.avhomesinc.com.

About TPG

TPG is a leading global private investment firm founded in 1992 with $56.7 billion of assets under management and offices in San Francisco, Fort Worth, Austin, Beijing, Chongqing, Hong Kong, London, Luxembourg, Melbourne, Moscow, Mumbai, New York, Paris, São Paulo, Shanghai, Singapore and Tokyo. TPG has extensive experience with global public and private investments executed through leveraged buyouts, recapitalizations, spinouts, growth investments, joint ventures and restructurings. The firm has committed more than $2 billion of equity to 10 real estate investments since 2009. TPG’s real estate transactions have included ST Residential, Catellus Development Corporation, Taylor Morrison Home Corporation, Parkway Properties, Inc., Merin BV, M West Holdings, L.P., Woolgate Exchange building in the City of London, and the pending acquisition of Assisted Living Concepts, Inc., among others. For more information visit www.tpg.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of AV Homes, Inc. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this press release. Although our management believes these expectations, estimates, or projections to be reasonable as of the date made, forward-looking statements are inherently subject to significant business risks, economic and competitive uncertainties, or other contingencies which could cause our actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause our actual results or performance to differ materially from our forward-looking statements include the following: (1) the transaction described in this press release not be completed, or completed within the expected timeframe; (2) the costs or difficulties relating to the transaction may be greater than expected and may adversely affect our results of operations and financial condition; (3) the expected benefits of the transaction, including acceleration of the implementation of our strategic plan, may take longer than anticipated to achieve and may not be achieved in the entirety or at all; and (4) the factors set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2012, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and in our other filings with the Securities and Exchange Commission (the “SEC“), which filings are available on www.sec.gov. Readers are cautioned not to place undue reliance on any forward-looking statements contained herein, which reflect management’s opinions only as of this press release. AV Homes disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

Additional Information

AV Homes will file a proxy statement in connection with a special meeting to approve the convertibility of the preferred stock issued in the transaction. The proxy statement and any other relevant documents filed with the SEC concerning AV Homes are (or will be, when filed) available free of charge at http://www.sec.gov and under the “Financial Information” section of the Investor Relations page at http://www.avhomesinc.com. Stockholders should read carefully the proxy statement and the accompanying proxy card when they become available before making any voting decision.

AV Homes, its directors, and certain of its officers and other employees are participants in the solicitation of proxies from AV Homes’ stockholders in connection with the special meeting. Important information concerning the identity and any interests of these persons will be available on a Schedule 14A that AV Homes will file with the SEC shortly.

Contacts: Contact for AV Homes:
          Ken Plonski
          480-214-7408
          k.plonski@avhomesinc.com

          Contact for TPG:
          Lisa Baker
          914-725-5949
          lisa@blicksilverpr.com

(MPET) to Present at the Global Hunter Securities 100 Energy Conference

DENVER, June 18, 2013 /PRNewswire/ — Magellan Petroleum Corporation (“Magellan” or the “Company”) (NASDAQ: MPET) announced today that the Company will be presenting at the Global Hunter Securities 100 Energy Conference to be held in Chicago, Illinois, on June 24 to 26, 2013.

Tom Wilson, President and Chief Executive Officer, is scheduled to present on Wednesday, June 26, 2013, at approximately 4:00 PM Central Time.  Presentation materials will be available in the Investor Relations section of the Company’s website at www.magellanpetroleum.com.

ABOUT MAGELLAN
Magellan Petroleum Corporation is an independent oil and gas exploration and development company with assets in the US, Australia, and the UK.  The Company is primarily focused on the development of a CO₂-enhanced oil recovery (“CO₂-EOR)” program at Poplar Dome in eastern Montana.  Historically active in Australia, Magellan operates two gas fields onshore Northern Territory and an exploration block in the Bonaparte Basin, offshore Northern Territory.  Magellan also maintains a large acreage position onshore the UK prospective for unconventional shale oil and gas production.  Magellan is headquartered in Denver, Colorado.  The Company’s mission is to enhance shareholder value by maximizing the full potential of existing assets.  Magellan routinely posts important information about the Company on its website at www.magellanpetroleum.com.

For further information, please contact:
Matthew Ciardiello, Manager, Investor Relations at 720.484.2404 or IR@magellanpetroleum.com

Alvarion® (ALVR) Intros BreezeULTRA™ Point-To-Point w/ 500 Mbps Throughput

A Carrier-Grade Backhaul Solution Offers a Unique Set of Features Including Auto Failover and Recovery Safeguard, Data Resilience and Integrity

Successful Beta Test Completed at Leading Agricultural Manufacturer in Turkey

SINGAPORE, June 18, 2013 (GLOBE NEWSWIRE) — CommunicAsia 2013 — Alvarion^® Ltd. (Nasdaq:ALVR), a global provider of optimized wireless broadband solutions addressing the connectivity, coverage and capacity challenges of public and private networks, today unveiled the BreezeULTRA™ dual radio, a high capacity point-to-point platform delivering 500 Mbps throughput.

The BreezeULTRA dual radio is based on 802.11n technology and takes advantage of 802.11ac channel combining techniques providing a high capacity 500 Mbps throughput per link and greater reliability. The channel combining technique (20+20 MHz and 40+40 MHz) allows the dual radio to be configured to use two frequency bands transmitting simultaneously, optimizing available bandwidth and achieving maximum throughput. A unique auto failover and recovery safeguard feature embedded within a single link ensures greater system availability as traffic is automatically switched over to the second frequency if experiencing interference.

“The BreezeULTRA dual radio draws on Alvarion’s long-standing tradition of radio innovation. It is currently the only point-to-point platform that combines this unique set of features of high capacity, radio redundancy, and data resilience and integrity in a single box, offering our customers a distinctive value proposition at a competitive price,” said Assaf Katan, Acting Chief Executive Officer of Alvarion.

With exceptional reliability and carrier-grade Quality of Service (QoS), the new BreezeULTRA dual radio offers a better customer experience and the lowest cost per Mbps on the market. Available in the unlicensed 5 GHz frequency band, it is well suited for a wide range of applications such as backhaul in the telecom market, smart cities, oil and gas, education, video surveillance and public safety.

The single radio BreezeULTRA is software upgradable to the dual radio version, enabling a “pay as you grow” approach.

Successful Beta Test Completed

The BreezeULTRA dual radio has been deployed over the past several weeks at certain facilities operated by the Keskinoğlu Group, a leading agricultural manufacturer in Turkey. Replacing a competitor’s solution, the BreezeULTRA is providing database backup between locations.  The network was deployed by NET ILETISIM, Alvarion’s partner in Turkey.

Following the completion of the Beta test, the Keskinoğlu Group made the following statement:  “We have been so pleased with the performance of the BreezeULTRA dual radio that we placed our order for the solution to be permanently installed before the trial ended. The BreezeULTRA dual radio proved to be the cost effective solution which met our requirements for bandwidth and reliability.”

“We strive to offer our customers the best networking solutions available. Therefore, we were eager to take part in testing this innovative solution from Alvarion and are pleased with the results and the response from our customer,” Gamze Şentürk, International Sales Manager, NET ILETISIM. “Given its feature set, the BreezeULTRA is a truly competitive point-to-point solution on the market.”

Follow Alvarion on Twitter

See Alvarion on LinkedIn

About NET ILETISIM

NET ILETISIM has been working with New Generation Networking Solutions for over ten years and has continued to excel in product advancement in Wireless Networking Technology. NET ILETISIM have gained valuable experience installing Point-to-Point, Point-to-Multi-Point, Outdoor Wi-Fi, Mesh Networking Metro zone and Fixed & Mobile WiMAX solutions in private networks of all types, from small enterprises to large corporations, government and municipalities, utility companies, educational and financial institutions. NET ILETISIM also specializes in Microwave Backhauling solutions for telecom and GSM operators.

NET ILETISIM is a distributor and provider of complete wireless networking solutions in Turkey, Uzbekistan, Azerbaijan, Kazakhstan, Tajikistan and Turkish Republic of Northern Cyprus. NET ILETISIM’s product offerings are leading names in the industry. (www.netiletisim.net/)

About Keskinoğlu

The 3600 employees working under the roof of Keskinoğlu have adopted and sustained the philosophy of the late Ismail Keskinoğlu, who is well-known for being the founder of Keskinoğlu Group. The best way to reflect the corporate culture of Keskinoğlu is to have a look at the beliefs and experiences of our unforgettable leader Ismail Keskinoğlu.

About Alvarion

Alvarion Ltd. (Nasdaq:ALVR) provides optimized wireless broadband solutions addressing the connectivity, coverage and capacity challenges of telecom operators, smart cities, security, and enterprise customers. Our innovative solutions are based on multiple technologies across licensed and unlicensed spectrums. (www.alvarion.com)

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Alvarion’s management and are subject to various factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: our failure to fully implement our 2012 turnaround plan, our inability to reallocate our resources and rationalize our business in a more efficient manner, potential impact on our business of the current global macro-economic uncertainties, the inability of our customers to obtain credit to purchase our products as a result of global credit market conditions, the failure to fund projects under the U.S. broadband stimulus program, continued delays in 4G license allocation in certain countries; the failure of the products for the 4G market to develop as anticipated; our inability to capture market share in the expected growth of the 4G market as anticipated, due to, among other things, competitive reasons or failure to execute in our sales, marketing or manufacturing objectives; the failure of our strategic initiatives to enable us to more effectively capitalize on market opportunities as anticipated; delays in the receipt of orders from customers and in the delivery by us of such orders; our failure to fully and effectively integrate the business and technology of Wavion Inc., acquired by us in November 2011, into our products and realize the expected synergies from the acquisition; the failure of the markets for our (including Wavion’s) products to grow as anticipated; our inability to further identify, develop and achieve success for new products, services and technologies; increased competition and its effect on pricing, spending, third-party relationships and revenues; our inability to establish and maintain relationships with commerce, advertising, marketing, and technology providers; our inability to comply with covenants included in our financing agreements; the fact that we will need to obtain additional sources of funding in order to continue our operations at their current anticipated levels and that there are no assurances that such funding will be available on favorable terms or at all, either through equity issuances or asset sales; and other risks detailed from time to time in the Company’s annual reports on Form 20-F as well as in other filings with the U.S. Securities and Exchange Commission.

Information set forth in this press release pertaining to third parties has not been independently verified by Alvarion and is based solely on publicly available information or on information provided to Alvarion by such third parties for inclusion in this press release. The web sites appearing in this press release are not and will not be included or incorporated by reference in any filing made by Alvarion with the U.S. Securities and Exchange Commission, which this press release will be a part of.

The information in this press release is provided solely for information purposes, and is not a commitment, promise or legal obligation to deliver any products, features and/or functionalities, and should not be relied upon in making purchasing decisions. The development, release and timing of any products, features and/or functionalities described remains at the sole discretion of Alvarion. If and when any products, features and/or functionalities are offered for sale by Alvarion, they will be sold under agreed upon terms and conditions. This information may not be incorporated into any contractual agreement with Alvarion or its subsidiaries or affiliates. Alvarion makes no representations or warranties with respect to the contents of this press release, and specifically disclaims any express or implied warranties of merchantability or fitness for any particular purpose.

To receive Alvarion’s press releases please contact Sivan Farfuri, sivan.farfuri@alvarion.com or +972.3.767.4333. Please see the Investor section of the Alvarion website for more information: http://www.alvarion.com/investors.

Alvarion®, its logo and certain names, product and service names referenced herein are either registered trademarks, trademarks, trade names or service marks of Alvarion Ltd. in certain jurisdictions. All other names are or may be the trademarks of their respective owners.

CONTACT: Investor & media Contacts:

         Avi Stern, CFO
         +972.3.767.4333
         avi.stern@alvarion.com

         Elana Holzman, VP IR
         +972.3.645.7892
         elana.holzman@alvarion.com

RiT Technologies (RITT) Reports Results of Annual Meeting of Shareholders

TEL AVIV, Israel, June 18, 2013 /PRNewswire/ —

RiT Technologies (NASDAQ: RITT) (the “Company”), today announced that at its Annual General Meeting of Shareholders held on June 17, 2013, all of the items on the meeting’s agenda were approved by the Company’s shareholders. These items were: (1) the reelection of three directors; (2) the reelection of an external director; (3) the reappointment of independent auditors; (4) approval of the terms of procurement of the liability insurance policy covering the Company’s directors and officers; (5) approval of the increase of the Company’s authorized share capital and approval of related amendments to the Company’s Memorandum and Articles of Association; (6) approval of the grant of stock options to the CEO; (7) approval of the Representative Agreement with IntElorg Pte Ltd. (Singapore); (8) approval of the terms and framework of compensation to an employee related to the Company’s controlling shareholder; and (9) approval of the Company’s compensation policy for directors and officers.

About RiT Technologies

RiT is a leading provider of intelligent infrastructure management (IIM) solutions and a developer of a new revolutionary indoor optical wireless technology solution. Our IIM products provide and enhance security and network utilization for data centers, communication rooms and work space environments. They help companies plan and provision, monitor and troubleshoot their communications networks, maximizing utilization, reliability and physical security while minimizing unplanned downtime. RiT’s IIM solutions are deployed around the world, in a broad range of organizations, including: data centers, enterprises, corporations, government agencies, financial institutions, airport authorities, healthcare institutions, and education institutions. RiT’s indoor optical wireless technology solution will help our clients streamline deployment, reduce infrastructure design, installation and maintenance complexity and enhance security in a cost effective way. RiT’s shares are traded on the Nasdaq exchange under the symbol RITT.

For more information, please visit our website: http://www.rittech.com

Safe Harbor Statement

In this press release, all statements that are not purely about historical facts, including, but not limited to, those in which we use the words “believe,” “anticipate,” “expect,” “plan,” “intend,” “estimate”, “forecast”, “target”, “could” and similar expressions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  While these forward-looking statements represent our current judgment of what may happen in the future, actual results may differ materially from the results expressed or implied by these statements due to numerous important factors, including, but not limited to, those described under the heading “Risk Factors” in our most recent Annual Report filed with the Securities and Exchange Commission (SEC) on Form 20-F, which may be revised or supplemented in subsequent reports filed with the SEC.  These factors include, but are not limited to, the following: our ability to raise additional financing, if required; the continued development of market trends in directions that benefit our sales; our ability to maintain and grow our revenues; our dependence upon independent distributors, representatives and strategic partners; our ability to develop new products and enhance our existing products; the availability of third-party components used in our products; the economic condition of our customers; the impact of government regulation; and the economic and political situation in Israel.  We are under no obligation, and expressly disclaim any obligation, to update the forward-looking statements in this press release, whether as a result of new information, future events or otherwise.

COMPANY CONTACT:

Elan Yaish, CFO
+972-77-270-7210
elan.yaish@rittech.com

Six Months After Publication of Key Studies (CBMX) Sees Growth in Prenatal Testing Adoption

Growth Driven by Data Published in New England Journal of Medicine Showing Value of Chromosomal Microarray Analysis

IRVINE, Calif., June 18, 2013 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that its volumes of prenatal testing have shown a significant uptick since data from two National Institutes of Health (NIH) studies showed the value of chromosomal microarray analysis (CMA).

The larger study (published in conjunction with the National Institute of Child Health and Human Development [NICHD]), which had over 4,400 patients enrolled, was published in the New England Journal of Medicine (NEMJ) in December 2012 and presented at the annual meeting of the Society for Maternal-Fetal Medicine in February, concluded that CMA identified additional clinically significant genetic abnormalities compared to traditional karyotyping when testing prenatal samples. CombiMatrix is the only publicly-traded company that specializes in CMA.

“The NICHD study clearly demonstrated the superiority of microarrays over traditional karyotyping,” said Jim Goldberg, MD of San Francisco Perinatal Associates. “Due to the strength of the data in that study, we now counsel patients on the availability of microarray testing and offer this option to them as a first tier test.” Dr. Goldberg reiterated, “The clinical utility of microarrays are their ability to detect chromosomal copy number abnormalities that are missed by traditional karyotyping. The accuracy of microarray, coupled with the test’s fast turn-around-time, helps reduce patients’ anxiety by providing comprehensive results as we move toward this new standard of care.”

Some clinicians have been slow to adopt microarray testing because of concerns about variants of uncertain significance (VOUS). Dr. Goldberg emphasizes, “These types of findings are a routine part of prenatal diagnosis as a whole. Microarray testing identifies clinically significant chromosomal abnormalities that have gone undetected by karyotyping. As we learn more about these undetected chromosomal copy number changes, clinicians will become more comfortable explaining their significance to patients.”

At CombiMatrix, volumes of testing for both miscarriage management and prenatal genetic testing have grown rapidly, as previously reported in the Company’s first quarter 2013 earnings release.

“We believe that the very clear data published in the NEJM on both stillbirths and on invasive procedures highlight the value of CMA and is driving the uptick in our prenatal testing volumes,” CombiMatrix President and CEO Mark McDonough said. “The data has generated momentum that tells us, first, we made the correct decision when we decided to make a strategic shift to focus on the developmental markets where CMA is becoming the standard of care. But second, it also shows that we continue to take market share from our competitors. We are excited and well positioned to help drive the conversion from karyotyping to microarrays over the next several quarters.”

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory which offers DNA-based testing services to the prenatal, pediatric and oncology markets. The Company performs genetic testing utilizing Microarray, FISH, PCR and G-Band Chromosome Analysis. CMDX offers prenatal and pediatric testing services for the detection of abnormalities of genes at the DNA level beyond what can be identified through traditional technologies. CMDX was also the first commercial clinical laboratory in the United States to make comprehensive DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate and brain tumors, available to oncology patients and medical professionals. Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “goal,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” “objective,” similar expressions, and variations or negatives of these words and include, but are not limited to, statements regarding the advantages and efficacy of CMA over standard karyotyping. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: market acceptance of CMA as a preferred method over karyotyping; the rate of transition to CMA from karyotyping; our ability to successfully expand the base of our customers and strategic partners, add to the menu of our diagnostic tests in both of our primary markets, develop and introduce new tests and related reports, optimize the reimbursements received for our testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, allow access to samples earlier in the testing continuum, steadily increase the size of our customer rosters in both developmental medicine and oncology; our ability to attract and retain a qualified sales force; rapid technological change in our markets; changes in demand for our future products; legislative, regulatory and competitive developments; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.

CONTACT: Company Contact:
         Mark McDonough
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624

         Media Contact:
         Len Hall
         VP, Media Relations
         Allen & Caron
         Tel (949) 474-4300
         len@allencaron.com

         Investor Relations Contact:
         John Baldissera
         BPC Financial Marketing
         Tel (800) 368-1217

Gevo (GEVO) Resumes Commercial Production of Isobutanol

ENGLEWOOD, Colo., June 18, 2013 (GLOBE NEWSWIRE) — Gevo, Inc. (Nasdaq:GEVO) today announced that it has resumed commercial production of isobutanol at its Luverne, Minn. plant in single train mode, successfully utilizing its proprietary Gevo Integrated Fermentation Technology^® (GIFT^®).

“I am pleased to report that we have been successful in operating our full-scale fermentation and our GIFT^® separation system that separates the isobutanol from the fermentation broth. This serves to further validate our technology as we had not previously run the GIFT^® system at full scale. I can now say that it runs beautifully,” noted Patrick Gruber, Gevo’s Chief Executive Officer.

Gruber continued, “As you may recall, we had some microbial contamination in our plant that we have since learned to control and manage. The fixes included changing the fermentation conditions and related operating parameters, making equipment modifications to improve sanitization, and, most importantly, improving our operating discipline—the procedures we use at the plant.

“We plan to be producing isobutanol and operating throughout the rest of this year. While we are currently operating a single production train, we plan on bringing all of our fermenters and GIFT^® systems online in the third and fourth quarters, testing run rates, then ramping up production and sales in 2013 and 2014,” noted Gruber.

Gevo will sell the isobutanol it produces, using it for market development in the specialty chemicals market, the specialty oxygenated fuel blendstock market, and as a building block to make jet fuel and chemical products such as paraxylene for PET used in the production of bottles and fibers.

About Gevo

Gevo is a leading renewable chemicals and next-generation biofuels company. Gevo’s patent-protected, capital-light business model converts existing ethanol plants into bio-refineries to make isobutanol. This versatile chemical can be directly integrated into existing chemical and fuel products to deliver environmental and economic benefits. Gevo has executed initial commercial-scale production runs at its isobutanol facility in Luverne, Minn., and has a marquee list of partners including The Coca-Cola Company, Sasol Chemical Industries, and LANXESS, Inc., an affiliate of LANXESS Corporation, among others. Gevo is committed to a sustainable bio-based economy that meets society’s needs for plentiful food and clean air and water. For more information, visit www.gevo.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements that are not purely statements of historical fact, and can sometimes be identified by our use of terms such as “intend,” “expect,” “plan,” “estimate,” “future,” “strive” and similar words. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and the company undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although the company believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2012, as amended, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Gevo.

CONTACT: Media Contact:
         Steve Halsey
         Gibbs & Soell for Gevo
         T: (212) 697-2600
         shalsey@gibbs-soell.com

         Investor Contact:
         Chelsea DeLong
         PR & Marketing Coordinator
         T: (303) 588-6306
         cdelong@gevo.com

China Sunergy (CSUN) Starts to Ship from Turkey Plant

NANJING, China, June 14, 2013 /PRNewswire/ — China Sunergy Co., Ltd. (NASDAQ: CSUN) (“China Sunergy” or “the Company”), a specialized solar cell and module manufacturer, today announced that it has begun shipping solar modules from its plant in Istanbul, Turkey, and will deliver a total of approximately 6.4MW from mid-June to August 2013 to a well-known French customer.

China Sunergy currently has a total production capacity of 100MW in solar cells and 300MW in solar modules at its Turkey facility. Being the Company’s second largest production base, the plant will enhance the Company’s global production chain and efficiently serve customers across Europe and globally.

Mr. Stephen Cai, CEO of China Sunergy said, “We are very delighted to announce our first contract win from Europe for the Turkey plant. The modules will be shipped directly from Istanbul, Turkey to France, which marks a significant milestone in our enhanced global production chain, as we believe our Turkey plant provides us with an effective buffer against the negative impact due to Europe’s anticipated anti-dumping tariffs. We believe there are enormous demands for clean, green and affordable around the world, and we will continue to focus on technology innovation, to provide the most efficient and reliable solutions to our customers.”

About China Sunergy Co., Ltd.

China Sunergy Co., Ltd. (NASDAQ:CSUN) designs, manufactures and delivers high efficiency solar cells and modules to the world from its production centers based in China and Turkey. China Sunergy also invests in high potential solar projects. Founded in 2004, China Sunergy is well known for its advanced solar cell technology, reliable product quality, and excellent customer service.

For more information, please visit http://www.csun-solar.com.

Investor and Media Contacts:

China Sunergy Co., Ltd.
Elaine Li
Phone: + 86 25 5276 6696
Email: Elaine.li@chinasunergy.com

Asia Bridge Group Limited
Wendy Sun
Phone: + 86 10 8556 9033
Email: wendy.sun@asiabridgegroup.com

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts in this announcement are forward-looking statements. These forward-looking statements are based on current expectations, assumptions, estimates and projections about the Company and the industry, and involve known and unknown risks and uncertainties, including but not limited to, the Company’s ability to raise additional capital to finance the Company’s activities; the Company’s customers’ financial condition and creditworthiness, and their ability to settle accounts receivables; the effectiveness, profitability, and the marketability of its products; litigations and other legal proceedings, including any decisions by the US International Trade Committee and Department of Commerce on the petitions filed; the economic slowdown in China and elsewhere and its impact on the Company’s operations; demand for and selling prices of the Company’s products, execution of our strategy to expand into downstream solar power businesses, the future trading of the common stock of the Company; the ability of the Company to operate as a public company; the period of time for which its current liquidity will enable the Company to fund its operations; the Company’s ability to protect its proprietary information; general economic and business conditions; the volatility of the Company’s operating results and financial condition; the Company’s ability to attract or retain qualified senior management personnel and research and development staff; future shortage or availability of the supply of raw materials; impact on cost-competitiveness as a result of entering into long-term arrangements with raw material suppliers and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

Uranium Resources (URRE) Appoints Jeffrey L. Vigil as Vice President and CFO

Consolidating Corporate Functions in New Denver Headquarters

LEWISVILLE, Texas, June 14, 2013 (GLOBE NEWSWIRE) — Uranium Resources, Inc. (Nasdaq:URRE) (URI) today announced that Jeffrey L. Vigil was appointed Vice President and Chief Financial Officer effective June 14, 2013. Mr. Vigil, who most recently was Senior Vice President and Chief Accounting Officer at Energy Fuels Inc. (TSX:EFR), succeeds Thomas H. Ehrlich, who resigned to pursue other interests.

Christopher M. Jones, President and CEO of URI, stated, “Jeff is a mining industry financial veteran with over thirty years of financial management experience in both production stage and development stage enterprises.  We are excited about Jeff’s passion for nuclear energy and the significant industry experience he brings to URI.  We believe his experience will play a significant role in the execution of our strategic plan to return to production and strengthens our position to expand our company.”

During his tenure at Energy Fuels, Mr. Vigil held various financial positions including CFO between 2009 and 2012. He managed financial and management reporting, equity financings, tax planning and compliance, treasury functions and risk management for Energy Fuels. He also managed financial, operational and legal due diligence for a number of acquisitions. From 1996 to 2007, Mr. Vigil served as CFO for Koala Corporation, which had approximately 350 employees and operated divisions in New York, Florida, Texas, Oregon, Colorado and British Columbia. Mr. Vigil is a graduate of the University of Wyoming with a BS in Accounting and is a licensed Certified Public Accountant in the State of Colorado.

Mr. Ehrlich first joined URI in 1987 and most recently served as Vice President and Chief Financial Officer for URI.  “Tom has been an invaluable member of the executive team and we thank him for all his contributions and wish him well in his future endeavors,” stated Paul K. Willmott, Chairman of the Board of URI.

URI continues efficiency and cost reduction initiatives

The Company also announced that it will close its offices in Lewisville, Texas and relocate its headquarters to its offices in Denver, Colorado. It is expected that the move will be completed by the end of the third quarter of 2013.

Mr. Jones added, “These changes support our focus on cost containment and management of expenses so that we can minimize our cash burn rate. We also believe the consolidation will strengthen our organization, support the development of our Texas and New Mexico properties and position us to efficiently and effectively grow our business.”

About Uranium Resources, Inc.

Uranium Resources, Inc. explores for, develops and mines uranium. Since its incorporation in 1977, URI has produced uranium by in-situ recovery (ISR) methods in Texas and currently has a number of initiatives underway to return the Company to production. URI has over 206,600 acres of uranium mineral holdings and 144.8 million pounds of in-place mineralized uranium material in New Mexico and an NRC license to produce up to 3 million pounds of uranium per year. URI has an additional 664,000 pounds of in-place reserves in Texas. The Company acquired these properties over the past 20 years along with an extensive information database of historic drill hole logs, assay certificates, maps and technical reports.

Uranium Resources routinely posts news and other information about the Company on its website at www.uraniumresources.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects,” “estimates,” “projects,” “anticipates,” “believes,” “could,” and other similar words. All statements addressing operating performance, events, or developments that the Company expects or anticipates will occur in the future, including but not limited to statements relating to the Company’s mineralized uranium materials, development plans for properties in South Texas and New Mexico, the timing for and savings associated with consolidation activities, plans for managing capital and returning to production are forward-looking statements. Because they are forward-looking, they should be evaluated in light of important risk factors and uncertainties. These risk factors and uncertainties include, but are not limited to, the Company’s ability to raise additional capital in the future, spot price and long-term contract price of uranium, the outcome of negotiations with the Navajo Nation, the Company’s ability to reach agreements with current royalty holders, weather conditions, operating conditions at the Company’s mining projects, government and tribal regulation of the mining industry and the nuclear power industry, world-wide uranium supply and demand, availability of capital, timely receipt of mining and other permits from regulatory agents, maintaining sufficient financial assurance in the form of sufficiently collateralized surety instruments and other factors which are more fully described in the Company’s documents filed with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on the Company’s forward-looking statements. Except as required by law, the Company disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this news release.

CONTACT: Investor Contact:
         Deborah K. Pawlowski
         Kei Advisors LLC
         Phone: 716.843.3908
         Email: dpawlowski@keiadvisors.com

(HYGS) Largest Power to Gas Facility in the World Now Operational

MISSISSAUGA, Ontario, June 14, 2013 (GLOBE NEWSWIRE) — Hydrogenics Corporation (Nasdaq:HYGS) (TSX:HYG) a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today announced that the largest Power to Gas facility in the world went “live” this week with the first direct injection of hydrogen into a gas pipeline using Hydrogenics technology.

Last year, Hydrogenics received an order from E.ON for a “Power-to-Gas” project in Germany. The two megawatt energy storage facility, located in Falkenhagen in northeast Germany, uses surplus renewable energy sources to produce hydrogen for storage in the country’s existing natural gas pipeline network. The facility, delivered at the end of 2012 and commissioned over the first quarter of 2013 has passed all tests and all required permits and certifications have now been granted for the operation of this facility. Dr. Urban Keussen, Senior Vice President Technology & Innovation of E.ON, witnessed the milestone event this week.

This Power to Gas facility, converts renewable generation when it is not needed into renewable power, fuel or heat where and when it is needed. With this facility now in full operation E.ON Gas Storage is feeding 640 m³ per hour into the local natural gas grid (ONTRAS).

For Hydrogenics this has been a turnkey Power to Gas project which included supply, installation, connection and commissioning of the hydrogen production facility including gas compression, master controls, as well as a five year service and maintenance agreement.

About Energy Storage in Germany

Germany is a key energy storage player in Europe thanks to its leading position in terms of installed capacity of fluctuating renewables. In 2011, generation from renewable sources in Germany accounted for 20 percent of total electricity generation. If Germany is to meet its ambitious goals of getting a third of its electricity from renewable energy by 2020, at least 50 percent by 2030 and 80 percent by 2050, it must find a way to store huge quantities of electricity in order to make up for the intermittency of renewable energy. The intermittency of wind and solar will make it almost impossible for German electric utilities to provide clean, affordable, and reliable power to industry and consumers, at the high levels of penetration by intermittent renewables that Germany is trying to achieve. Utility-scale energy storage will be a key part of this future German energy plan. According to the German Energy Agency (DENA), investments in the two-digit billion range will be required if Germany intends to meet its stated objective of getting a third of its electricity consumption from renewable resources in 2020.

About Hydrogenics

Hydrogenics Corporation (www.hydrogenics.com) is a globally recognized developer and provider of hydrogen generation and fuel cell products and services, serving the growing industrial and clean energy markets of today and tomorrow. Based in Mississauga, Ontario, Canada, Hydrogenics has operations in North America and Europe.

Forward-looking Statements

This release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995, and under applicable Canadian securities law. These statements are based on management’s current expectations and actual results may differ from these forward-looking statements due to numerous factors, including: our inability to increase our revenues or raise additional funding to continue operations, execute our business plan, or to grow our business; inability to address a slow return to economic growth, and its impact on our business, results of operations and consolidated financial condition; our limited operating history; inability to implement our business strategy; fluctuations in our quarterly results; failure to maintain our customer base that generates the majority of our revenues; currency fluctuations; failure to maintain sufficient insurance coverage; changes in value of our goodwill; failure of a significant market to develop for our products; failure of hydrogen being readily available on a cost-effective basis; changes in government policies and regulations; failure of uniform codes and standards for hydrogen fuelled vehicles and related infrastructure to develop; liability for environmental damages resulting from our research, development or manufacturing operations; failure to compete with other developers and manufacturers of products in our industry; failure to compete with developers and manufacturers of traditional and alternative technologies; failure to develop partnerships with original equipment manufacturers, governments, systems integrators and other third parties; inability to obtain sufficient materials and components for our products from suppliers; failure to manage expansion of our operations; failure to manage foreign sales and operations; failure to recruit, train and retain key management personnel; inability to integrate acquisitions; failure to develop adequate manufacturing processes and capabilities; failure to complete the development of commercially viable products; failure to produce cost-competitive products; failure or delay in field testing of our products; failure to produce products free of defects or errors; inability to adapt to technological advances or new codes and standards; failure to protect our intellectual property; our involvement in intellectual property litigation; exposure to product liability claims; failure to meet rules regarding passive foreign investment companies; actions of our significant and principal shareholders; dilution as a result of significant issuances of our common shares and preferred shares; inability of US investors to enforce US civil liability judgments against us; volatility of our common share price; and dilution as a result of the exercise of options; and failure to meet continued listing requirements of Nasdaq. Readers should not place undue reliance on Hydrogenics’ forward-looking statements. Investors are encouraged to review the section captioned “Risk Factors” in Hydrogenics’ regulatory filings with the Canadian securities regulatory authorities and the US Securities and Exchange Commission for a more complete discussion of factors that could affect Hydrogenics’ future performance. Furthermore, the forward-looking statements contained herein are made as of the date of this release, and Hydrogenics undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, unless otherwise required by law. The forward-looking statements contained in this release are expressly qualified by this.

CONTACT: Bob Motz, Chief Financial Officer
         (905) 361-3660
         investors@hydrogenics.com

(GRPN) G-Pass Reaches 1M Redemption Milestone on Deals for Live Events

Groupon (NASDAQ: GRPN) (www.groupon.com) today announced that, since its inception in April of 2012, G-Pass has allowed one million Groupon customers to bypass the box office line and head straight into the venue to enjoy their favorite band, take in an off-broadway show or cheer on the home team. The G-Pass ticketing system grants purchasers direct admission to events, eliminating the need to visit the box office to pick up tickets before entering a venue.

“Perfecting the customer experience is always a top priority Groupon,” said Greg Rudin, VP and general manager at Groupon. “G-Pass simply allows customers to worry less about getting into the venue and focus more on enjoying the event. And at the same time, it helps alleviate stress on box office partners.”

G-Pass has been adopted by hundreds of merchants across the United States and Canada, spanning categories such as music, sports, arts and theater and family events. For subscribers, this means access to presale opportunities, premium tickets and packages that enhance the experience, as well as access to some of the most sought-after events in the best venues. Gaining momentum, G-Pass has already issued more than 700,000 tickets so far this year; some of the noteworthy G-Pass deals include:

• Seattle Mariners home game
• Pitbull and Ke$ha concert in Chicago
• Blue Man Group in Boston
• The Joffrey Ballet’s “Othello”
• “Spider-Man Turn Off The Dark” in New York
• Bon Jovi: Because We Can – The Tour in North Jersey

About Groupon

Groupon (NASDAQ: GRPN) is a global leader in local commerce, making it easy for people around the world to search and discover great businesses at unbeatable prices. Groupon is reinventing the traditional small business world by providing merchants with a suite of products and services, including customizable deals, payments processing capabilities and point-of-sale solutions to help them attract more customers and run their operations more effectively. By leveraging the company’s global relationships and scale, Groupon offers consumers incredible deals on the best stuff to eat, see, do, and buy in 48 countries. With Groupon, shoppers discover the best a city has to offer with Groupon Local, enjoy vacations with Groupon Getaways, and find a curated selection of electronics, fashion, home furnishings and more with Groupon Goods. To subscribe to Groupon emails, visit www.Groupon.com. To learn more about the company’s merchant solutions and how to work with Groupon, visit www.GrouponWorks.com.

Codexis (CDXS) and Chemtex Achieve Key Commercial Milestone

Codexis (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, and Chemtex, a leader in chemical engineering and renewable processes, today announced the successful scale-up in the production of CodeXol^® detergent alcohols using cellulosic sugars. The scale-up was achieved at a 1,500 liter demonstration facility at Chemtex’s R&D complex in Tortona, Italy and is a key milestone in the ongoing effort initiated by the two companies to develop a fully integrated biomass to detergent alcohols technology. A combination of Chemtex’s commercially proven PROESA^® cellulosic sugar technology and Codexis’ CodeXyme^® 4X cellulase enzymes was used to produce cellulosic sugars from non-food biomass, while the CodeXol^® detergent alcohol fermentation process technology – which includes Codexis’ proprietary microorganism strain – converted these cellulosic sugars to detergent alcohols.

Guido Ghisolfi, President of Chemtex, said, “While the PROESA^® technology is proven at commercial scale for the production of cellulosic ethanol – as evidenced by the successful start-up of our commercial facility in Crescentino, Italy – this achievement is further proof that our platform cellulosic sugar technology is best-in-class for producing a broad range of bio-based chemicals using sustainable, non-food sources of biomass. It also validates our conviction that scaling up these technologies beyond the lab is key to enabling the learning curve towards commercial viability.”

John Nicols, President and CEO of Codexis, said, “This scale-up of CodeXol^® detergent alcohols represents what we believe is the world’s first successful large scale effort to produce commercially relevant detergent alcohols from a cellulosic biomass feedstock. We believe this scale-up demonstrates the robustness and efficacy of our CodeXyme^® cellulase enzymes and the ability of our CodeXol^® detergent alcohol technology to produce detergent alcohols at commercial specification with the potential to decrease manufacturing costs below incumbent production costs.”

Detergent alcohols are used to manufacture surfactants, which are key, active cleaning ingredients in consumer products such as shampoos, liquid soaps and laundry detergents. The annual global market for detergent alcohols, which are currently manufactured from natural oils and fats and petrochemicals, is approximately $4 billion and is expected to reach $5.5 billion by 2020. Codexis and Chemtex initiated an effort in 2011 to produce these high-value chemicals from sustainable, low-cost and non-food sources of biomass, which has the potential to offer attractive production economics compared to incumbent production routes.

About Codexis, Inc.

Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical production. Codexis’ proven technology enables scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development – from research to manufacturing. For more information, see www.codexis.com.

About Chemtex

Chemtex is a global engineering and technology company wholly-owned by Italy’s Gruppo Mossi & Ghisolfi (“M&G”). Chemtex specializes in delivering value-added project solutions for its clients in the bio-fuels, renewable chemicals, energy, environmental, petrochemical, polymers and fibers industries. The company benefits from over 60 years of success in process development and commercializing hundreds of plants worldwide. Chemtex International Inc., its North American Headquarters, is located in Wilmington, N.C.

Chemtex is a leader in chemical engineering and renewable processes. It has engineered and constructed the world’s first commercial-scale cellulosic ethanol facility in Crescentino, Italy for Beta Renewables producing cellulosic ethanol from locally sourced cellulosic biomass using its PROESA^® Process.

Codexis Forward-Looking Statements

This press release contains forward-looking statements relating to the ability of Codexis to produce CodeXol^® detergent alcohols at commercial specification and to decrease the manufacturing costs for CodeXol^® detergent alcohols below production costs for detergent alcohols currently on the market, the expected growth in the global detergent alcohols market over the next ten years and Codexis’ ability to offer attractive production economics for CodeXol^® detergent alcohols compared to incumbent production routes. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include Codexis’ ability to maintain license rights to a commercial scale expression system for enzymes that convert cellulosic biomass to sugars, the feasibility of commercializing bio-based chemicals derived from cellulose, the fluctuations in the price of and demand for certain commodities used in the production of fossil fuel-based chemical products, the cost or location of feedstocks used to manufacture bio-based chemicals and customer approval of Codexis’ potential bio-based chemical products. Additional factors that could materially affect actual results can be found in Codexis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2013, including under the caption “Risk Factors.” Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

(VSTA) Presents CardioSafe 3D™ and LiverSafe 3D™ Developments

SOUTH SAN FRANCISCO, CA — (Marketwired) — 06/17/13 — VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, presented key developments involving its CardioSafe 3D™ and LiverSafe 3D™ bioassay systems in poster presentations at the 11th Annual Meeting of the International Society of Stem Cell Research (ISSCR), the largest forum for stem cell and regenerative medicine professionals from around the world, held June 12 to 15, 2013, in Boston, Massachusetts.

Dr. Hai-Qing Xian, Senior Scientist, presented VistaGen’s poster entitled “Cardiotoxicity Assessment of Anti-Cancer Kinase Inhibitors using Human Pluripotent Stem Cell-Derived Cardiomyocyte Based Assays,” which detailed important developments demonstrating that CardioSafe 3D™, VistaGen’s high throughput, human heart cell-based bioassay, is a clinically predictive system for preclinical cardiac safety screening of anti-cancer drug candidates, including small molecule kinase inhibitors (KIs), a new category of drugs that have revolutionized cancer therapy due to decreased systemic toxicity and increased target cell efficacy compared to classic cancer drugs, as well as other therapeutic compounds. VistaGen demonstrated the utility of CardioSafe 3D™ to detect cardiac toxicities of well-known anti-cancer KIs, including imatinib, dasatinib, sunitinib, erlotinib and temsirolimus, which have been associated with adverse clinical cardiac events that were not detected during the drug development process. As demonstrated in the poster presentation, CardioSafe 3D™ successfully detected cardiotoxicity induced by representative compounds from different KI categories. Additionally, the bioassay system provided clues to the major mechanisms of cardiac cytotoxicity induced by each compound, thus enabling not only the identification of toxicities early in the drug development process, but also discovery of potential mechanisms of action.

Dr. Kristina Bonham, Senior Scientist, Hepatocyte Biology Project Leader, presented VistaGen’s poster entitled “Semi-quantitative assay of CYP3A4 allows the identification and selection of mature human stem cell derived hepatocytes,” which detailed developments indicating that LiverSafe 3D™, VistaGen’s human liver cell-based bioassay, can monitor the induction of the key metabolic enzyme, CYP3A4, and its expression level over time. Using an optimized protocol for the differentiation of hepatocyte-like cells, VistaGen demonstrated levels of CYP3A4 mRNA approaching that in human adult liver on a per cell basis. The reported data suggest that VistaGen’s liver cells have many of the functional properties of mature adult liver cells, enabling multiple functional analyses and providing a powerful system to evaluate the effects of drug candidates on CYP3A4 expression and liver function, offering a valuable aid for assessing potential drug candidates for toxicity and adverse drug-drug interactions.

H. Ralph Snodgrass, PhD, VistaGen’s President and Chief Scientific Officer, stated, “For the first time, our technology has caught up with the dreams and visions we had 15 years ago when we founded VistaGen. We now have the type and quality of human cell-based biological assay systems that provide real insight into both the therapeutic and toxic effects of new drug candidates long before they are ever tested in humans. Next-generation biological assays can now provide important preclinical human data that will increase the probability of selecting safer and effective therapeutics for clinical development.”

“It is evident from the mood, tone and scientific discussions throughout the ISSCR conference that this is the most exciting time in the history of stem cell research,” continued Dr. Snodgrass. “We anticipate that we will see an explosion over the next ten years in the contribution of human pluripotent stem cell-based biological assays to drug development, in parallel with phenomenal advancements in the therapeutic uses of mature cells and tissues derived from human pluripotent stem cells to treat some of the most intractable human diseases and conditions. Our team is truly fortunate and excited about being a part of this transformational process.”

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen’s drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories, after substantial investment in discovery and development, due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

VistaGen’s small molecule prodrug candidate, AV-101, has completed Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen’s Facebook page at http://www.facebook.com/VistaGen.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the success of VistaGen’s stem cell technology-based drug rescue, predictive toxicology and metabolism screening activities, further development of stem cell-based bioassay systems, and potentially improved cell therapies, for human blood system disorders or other diseases or conditions, clinical development and commercialization of AV-101 for neuropathic pain or any other disease or condition, its ability to enter into strategic predictive toxicology, metabolism screening, drug rescue and/or drug discovery, development and commercialization collaborations and/or licensing arrangements with respect to one or more drug rescue variants, cell therapies or AV-101, risks and uncertainties relating to the availability of substantial additional capital to support its research, drug rescue, development and commercialization activities, and the success of its research and development plans and strategies, including those plans and strategies related to any drug rescue variant or cell therapy identified and developed by VistaGen, or AV-101. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

For more information:
Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-244-9990 x224
Investor.Relations@VistaGen.com

Mission Investor Relations
IR Communications
Atlanta, Georgia
www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Qualstar (QBAK) Investor Presentation and Shareholder Conference Call

SIMI VALLEY, CA — (Marketwired) — 06/13/13 — Qualstar Corporation (NASDAQ: QBAK), a manufacturer of data storage solutions and high-efficiency power supplies, today announced that, in connection with management’s upcoming meetings with investors, it has filed its latest investor presentation with the Securities and Exchange Commission.

The company will hold a conference call on Wednesday, June 19, 2013 at 2 p.m. PT (5 p.m. Eastern) to discuss this presentation and take questions. All shareholders are encouraged to participate by dialing (800) 935-0893 or (847) 944-7376 and providing the passcode 35097942, or via the Internet using the link under the “Investors” section at www.qualstar.com. Please go to the Website at least 15 minutes early to register, download and install any necessary audio software. A replay of the Webcast will also be available after the live conference call.

In the investor presentation, Qualstar reviews the significant progress its new management team and independent board have made implementing the strategic plan that it announced in June 2012. By executing this plan, Qualstar is transforming its model from a high overhead, low margin, manufacturing-based company, to a highly scalable, high margin, low overhead, variable cost business that is positioned to expand its presence in both the storage and power supply markets. This is creating a platform for long-term growth, sustainable profitability, positive cash flow and increasing returns for investors. Qualstar also details in the investor presentation why shareholders should reject the latest attempt by BKF Capital Group, Inc., a publicly-held shell company controlled by Steven N. Bronson, to seek control of Qualstar without paying shareholders an appropriate control premium. Shareholders may obtain a copy of the investor presentation for free at the SEC’s website at http://www.sec.gov or under the “Investors” section of Qualstar’s website at http://www.qualstar.com.

“Over the next few weeks, I plan to meet with many of our shareholders, large and small, and share with them the progress we have made in implementing our strategic turnaround plan and transforming Qualstar for long-term growth, sustainable profitability, positive cash flow and increasing returns for investors,” said Lawrence D. Firestone, Qualstar’s President and Chief Executive Officer. “For close to 30 years, Bill Gervais, the founder of Qualstar, created innovative and technologically superior products that stood for quality and reliability in both the data storage and power conversion markets we serve. As we move forward with our transformation and strategic plan, we are proud of our accomplishments and excited by the opportunities now available to us as a streamlined sales and product development organization positioned for profitability and growth.”

Highlights of the investor presentation and recent accomplishments in the strategic turnaround plan for Qualstar include:

• Successful Outsourced Manufacturing Transition. The domestic outsourcing of manufacturing of Qualstar’s storage library products to CTS Electronics Manufacturing Solutions was accomplished in just 60 days, with the successful roll-out of the first outsourced RLS™ tape library product in May 2013. With the ISO-9000 certification and scalability of CTS’ manufacturing, Qualstar is now able to meet the needs of Tier 1 OEM customers and broaden its market opportunities.
• Gross Margin Improvements and Inventory Reductions. In just two quarters, Qualstar’s gross margins have already improved by 340 basis points as a result of lower material and fixed costs, as well as a 20% workforce reduction. The write-off of 45,000 square feet of manufacturing space, increased leverage of the supply chain, along with a 42% year-to-date reduction in required inventories, has also led to a significant improvement in working capital management.
• Significant Expansion of Worldwide Distribution. Strengthened sales teams in the storage and power supply businesses have delivered 40 new storage resellers, 6 new N2Power distributors, and 40 new N2Power design wins year-to-date. In addition, Qualstar recently joined the Technology Alliance Program of Hitachi Data Systems, a Tier 1 storage OEM, as a result of its newly-outsourced, highly scalable, and ISO-9000 certified outsourced manufacturing.
• Enhancement of Management, Board and Governance. In addition to a new CEO, CFO, and other senior executives, Qualstar has added three new independent, highly qualified directors who bring decades of relevant expertise and fresh perspective to enhance the breadth and depth of the Qualstar Board. Qualstar has also appointed an independent director to serve as Chairman of the Board.

About Qualstar Corporation

Qualstar, founded in 1984, is a diversified electronics manufacturer specializing in data storage and power supplies. Qualstar’s products are known throughout the world for high quality and Simply Reliable designs that provide years of trouble-free service. More information is available at www.qualstar.com or www.n2power.com or by phone at 805-583-7744.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains forward-looking statements relating to expectations, plans or prospects for Qualstar Corporation that are based upon the current expectations and beliefs of Qualstar’s management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Notwithstanding changes that may occur with respect to matters relating to any forward looking statements, Qualstar does not expect to, and disclaims any obligation to, publicly update any forward-looking statements whether as a result of new information, future events or otherwise. Qualstar, however, reserves the right to update such statements or any portion thereof at any time for any reason. In particular, the following factors, among others, could cause actual or future results to differ materially from those suggested by the forward-looking statements: Qualstar’s ability to successfully execute on its strategic plan and meet its long-term financial goals; Qualstar’s ability to successfully implement and recognize cost savings; Qualstar’s ability to develop and commercialize new products; industry and customer adoption and acceptance of Qualstar’s new products; Qualstar’s ability to increase sales of its products; the rescheduling or cancellation of customer orders; unexpected shortages of critical components; unexpected product design or quality problems; adverse changes in market demand for Qualstar’s products; increased global competition and pricing pressure on Qualstar’s products; and the risks related to actions of activist shareholders, including the amount of related costs.

For further information on these and other and other cautionary statements, please refer to the risk factors discussed in Qualstar’s filings with the U.S. Securities and Exchange Commission including, but not limited to, Qualstar’s Annual Report on Form 10-K for the fiscal year ended June 30, 2012, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of such Form 10-K, and any subsequently filed reports. All documents also are available without charge through the SEC’s website (www.sec.gov) or from Qualstar’s website (www.qualstar.com).

Additional Information and Where To Find It

In connection with its 2013 Annual Meeting of Shareholders, Qualstar has filed a definitive proxy statement and a WHITE proxy card with the SEC on June 4, 2013, and has mailed the definitive proxy statement and WHITE proxy card to its shareholders. WE URGE INVESTORS AND SHAREHOLDERS TO READ THE DEFINITIVE PROXY STATEMENT AND WHITE PROXY CARD FOR THE 2013 ANNUAL MEETING OF SHAREHOLDERS (INCLUDING ANY SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT QUALSTAR WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Shareholders will be able to obtain, free of charge, copies of the definitive proxy statement and any other documents filed by Qualstar with the SEC in connection with the 2013 Annual Meeting at the SEC’s website (www.sec.gov), at Qualstar’s website (www.qualstar.com) or by writing to Mr. Lawrence D. Firestone, President and Chief Executive Officer, Qualstar Corporation, 3990-B Heritage Oak Court, Simi Valley, CA 93063. In addition, copies of the definitive proxy materials may be requested from the Company’s proxy solicitor, MacKenzie Partners, Inc., 105 Madison Avenue, New York, NY 10016 or toll-free at (800) 322-2885.

Certain Information Regarding Participants in the Solicitation

Qualstar, its directors, nominees for director and certain officers, employees and other persons are deemed to be participants in the solicitation of proxies from shareholders in connection with the 2013 Annual Meeting of Shareholders. Information regarding the interests of such participants is included in the definitive proxy statement and other relevant documents filed and to be filed by Qualstar with the SEC in connection with the proxy solicitation.

For more information, contact:

Mark H. Harnett / Paul Schulman
MacKenzie Partners, Inc.
(212) 929-5500

Vanessa Lehr/Annie Leschin
Investor Relations
StreetSmart Investor Relations

(ROSG) Medicare Administrator Final Local Coverage Determination Cancer Origin Test™

microRNA assay determined reasonable and necessary for providing an important niche in pathologic diagnoses of Cancer of Unknown Primary

PHILADELPHIA and REHOVOT, Israel, June 13, 2013 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Novitas Solutions, the designated Medicare Administrative Contractor (MAC) for the Company’s microRNA-based diagnostic assays, has issued for notice the final revised Local Coverage Determination (LCD) for Biomarkers in Oncology, which includes the Rosetta Cancer Origin Test^™, the Rosetta Lung Cancer Test^™ and the Rosetta Kidney Cancer Test^™ (formerly miRview® mets², lung and kidney assays).  The LCD will become effective as of August 1, 2013.

The final revised LCD confirms continued Medicare coverage for the Cancer Origin Test to identify Cancer of Unknown or Uncertain Primary (CUP) as originally reported in Novitas’ bulletin posted in June 2012, and for which they have been reimbursing the test at approximately $3,500 per test.

This final policy determination was based on peer-reviewed publications from clinical studies conducted internally at Rosetta Genomics and at world-renowned institutions that demonstrated the test’s clinical utility.

“The affirmed Medicare reimbursement and formal coverage determination is good news for patients and physicians grappling with a CUP diagnosis.  The published policy provides continued Medicare reimbursement and enables us to provide the Cancer Origin Test to the 45 million Medicare beneficiaries throughout the U.S. at no cost to the patient, thereby eliminating an adoption barrier for the physician ordering the test and for the patient.  Together with our recent credentialing agreements with two large U.S. Preferred Provider Organizations, the total number of covered lives and for which our Cancer Origin Test could be adjudicated as ‘in-network’ now exceeds 61 million, which means that one-in-five Americans are covered for the Rosetta Cancer Origin Test,” said Kenneth A. Berlin President and Chief Executive Officer of Rosetta Genomics.

“Importantly, this LCD affirms that our test is reasonable and necessary for providing an important niche in the pathologic diagnoses of CUP.  With more than 200,000 patients per year presenting with Cancer of Unknown or Uncertain Primary, and who may benefit from our Cancer Origin Test, this coverage reflects the importance of determining the tumor origin in hard-to-diagnose metastatic cancers and CUP.  This is particularly important as new, molecularly-targeted cancer treatments are developed.  We believe our Cancer Origin Test helps physicians to accurately diagnose tumor origin in order to optimize treatment,” he added.

The Company reports that in the LCD, Novitas still considers the Rosetta Lung Cancer Test and the Rosetta Kidney Cancer Test investigational and, as such, will not include those tests for Medicare coverage at this time.

“We continue to build the body of clinical data in support of the utility of our Lung Cancer Test and our Kidney Cancer Test in sub-classifying tumor types.  We believe that additional clinical data and peer-reviewed publications will support a favorable reimbursement decision for these tests in the future,” he concluded.

About Rosetta Cancer Testing Services (formerly the miRview^® product line)

Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). Rosetta Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to asbestos exposure.  The Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.  Rosetta’s assays are designed to provide objective diagnostic data; it is the treating physician’s responsibility to diagnose and administer the appropriate treatment.  In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Rosetta Cancer Origin Test™, 60,000 from the Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer Test™ and 226,000 patients from the Rosetta Lung Cancer Test™. The Company’s assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.rosettagenomics.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics.  Founded in 2000, Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta’s cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.  Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, Rosetta’s Cancer of Origin Test™, Rosetta’s development or commercialization of molecular diagnostics, the market acceptance of Rosetta’s cancer testing services, particularly the Rosetta Cancer Origin Test™, Rosetta’s development of personalized medicine products and services and Rosetta achieving and maintaining Medicare coverage for its’ tests constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the “Risk Factors” section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact:
Rosetta Genomics
Ken Berlin, President & CEO
(215) 382-9000, ext. 326
investors@rosettagenomics.com

Investor Contacts:
LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com

or

Bruce Voss
(310) 691-7100
bvoss@lhai.com

(VSTM) Receives Orphan Medicinal Product Designation in EU

Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

“We are pleased that the EMA recognizes the significant unmet medical need in mesothelioma,” said Christoph Westphal, M.D., Ph.D., Verastem Chairman and Chief Executive Officer. “This orphan drug designation provides us with a number of benefits in the development of VS-6063.”

VS-6063 is an orally-available, small molecule inhibitor of focal adhesion kinase (FAK). Research on the FAK signaling pathway has revealed a critical role for cancer stem cell survival and disease progression.

“Mesothelioma is a devastating disease with limited treatment options,” said Dr. Joanna Horobin, Verastem Chief Medical Officer. “We are working with investigators throughout Europe and internationally to bring a new treatment option for these patients.”

A biomarker test is being developed in conjunction with LabCorp (NYSE: LH) to identify a subgroup of mesothelioma patients low in a marker called Merlin. Approximately 40-50% of mesothelioma patients lack Merlin. Studies by Verastem and others have shown that Merlin-low mesothelioma cells and tumors appear to be particularly sensitive to FAK inhibition. Verastem’s clinical study is designed as an adaptive, double-blind, placebo-controlled trial to evaluate the effect of VS-6063 in both the overall patient population and also those whose tumors are Merlin-low.

“We are in discussions with regulatory agencies worldwide,” said Robert Forrester, Verastem President and Chief Operating Officer. “We plan to start the randomized, double-blind, placebo controlled trial of VS-6063 in mesothelioma later this summer.”

Under EMA guidelines, Orphan Medicinal Product Designation provides up to 10 years of potential market exclusivity if the product candidate is approved for marketing in the European Union and the orphan designation is maintained. Orphan status also permits EMA assistance in optimizing the candidate’s clinical development through participation in designing the clinical protocol and preparing the marketing application. Additionally, a drug candidate designated by the EMA as an Orphan Medicinal Product may qualify for a reduction in regulatory fees as well as a European Union-funded research grant.

In addition to the upcoming mesothelioma study, VS-6063 is currently being evaluated in a Phase 1/1b trial in combination with paclitaxel in patients with ovarian cancer.

Verastem has multiple programs targeting cancer stem cells in or entering clinical development in 2013. FAK inhibitor VS-4718 has received allowance from the FDA to initiate a Phase 1 trial in advanced solid tumors and the dual PI3K/mTOR inhibitor VS-5584 is currently in IND-enabling studies and is expected to enter clinical development in the second half of 2013.

About Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.

Forward-looking statements:

This press release includes forward-looking statements about the Company’s strategy, future plans and prospects, including statements regarding the development of the Company’s compounds, including VS-6063, VS-4718 and VS-5584, and the Company’s FAK, PI3K/mTOR and diagnostic programs generally, the timeline for clinical development and regulatory approval of the Company’s compounds including the impact of and any potential benefits from Orphan Medicinal Product Designation, and the structure of the Company’s planned clinical trials and estimates of the Company’s ability to fund operations. The words “anticipate,” “appear,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks that the preclinical testing of the Company’s compounds may not be predictive of the success of later clinical trials, that the Company will be unable to successfully complete the clinical development of its compounds, including VS-6063, VS-4718 and VS-5584, that the development of the Company’s compounds will take longer or cost more than planned, and that the Company’s compounds will not receive regulatory approval or become commercially successful products. Other risks and uncertainties include those identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 and in any subsequent SEC filings. The forward-looking statements contained in this presentation reflect the Company’s current views with respect to future events, and the Company does not undertake and specifically disclaims any obligation to update any forward-looking statements.

(LRAD) Corp. Receives $1.98 Million LRAD® Order from United States Navy

First Order from New Multi-Year Contract

SAN DIEGO, June 13, 2013 (GLOBE NEWSWIRE) — LRAD Corporation (NASDAQ: LRAD), the world’s leading provider of long range acoustic hailing devices (AHDs), announced today it has received a $1.98 million LRAD systems order from the United States Navy. The order, comprised of LRAD 100X™, LRAD 500X™ and LRAD 1000Xi™ systems, is scheduled for delivery before September 30, 2013.

“We’re pleased to receive this order, our first under the recently awarded multi-year $12.2 million firm-fixed-price, indefinite-delivery/indefinite-quantity contract for small, medium and large AHDs from the United States Navy’s Naval Surface Warfare Center,” commented Tom Brown, president and CEO of LRAD Corporation. “LRAD is the only AHD that meets all the rigorous specifications of the United States Navy.”

At distances up to 3,500 meters, LRAD systems have proven highly effective in anti-terrorism/force protection missions by broadcasting powerful deterrent tones and live or pre-recorded multi-language warnings, commands and instructions with unprecedented clarity and range. By communicating clearly over distance, LRAD systems create large standoff zones, unequivocally determine intent, resolve uncertain situations peacefully and save lives on both sides of the Long Range Acoustic Device®.

LRAD systems are deployed in more than 60 nations around the world including by U.S. and international naval forces and other military and security organizations.

About LRAD Corporation

LRAD Corporation is using long range communication to resolve uncertain situations peacefully and save lives on both sides of its proprietary Long Range Acoustic Device®. LRAD® systems are in service around the world in diverse applications including fixed and mobile military deployments, maritime security, critical infrastructure and perimeter security, commercial security, border and port security, law enforcement and emergency responder communications, emergency warning and mass notification, asset protection, and wildlife preservation and control. For more information about the Company and its LRAD systems, please visit www.lradx.com.

Forward-looking Statements: Except for historical information contained herein, the matters discussed are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on these statements. We base these statements on particular assumptions that we have made in light of our industry experience, the stage of product and market development as well as our perception of historical trends, current market conditions, current economic data, expected future developments and other factors that we believe are appropriate under the circumstances. These statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in the forward-looking statements. These risks and uncertainties are identified and discussed in our filings with the Securities and Exchange Commission. These forward-looking statements are based on information and management’s expectations as of the date hereof. Future results may differ materially from our current expectations. For more information regarding other potential risks and uncertainties, see the “Risk Factors” section of the Company’s Form 10-K for the fiscal year ended September 30, 2012.  LRAD Corporation disclaims any intent or obligation to update those forward-looking statements, except as otherwise specifically stated.

COMPANY CONTACT:
Robert Putnam
+1 858.676.0519
robert@lradx.com

CONTACT: Robert Putnam
         (858) 676-0519
         robert@lradx.com

WebMediaBrands Inc. (MBIS) Name and Ticker Update, New Website Launched

Mediabistro Inc. (Nasdaq:MBIS) today announced that, effective immediately, it has officially changed its corporate name from WebMediaBrands Inc. and its Nasdaq stock ticker symbol from WEBM.

Chairman and CEO Alan Meckler stated, “Since we adopted the name WebMediaBrands in 2009, Mediabistro has emerged as our leading line of business with brand name recognition in our intended market.” Mr. Meckler added, “In order to capitalize on this success and open doors for future growth opportunities, it is important that our name aligns with our most recognizable products and services. The Mediabistro brand is well-known worldwide for its leading job board, courses, editorial content, and trade shows for media professionals. We believe the corporate name Mediabistro Inc. better reflects our business as a whole.”

In conjunction with its corporate name change, Mediabistro’s homepage (http://mediabistro.com) has also been redesigned to reflect the company’s full suite of media content and services.

About Mediabistro Inc.

Mediabistro Inc. (Nasdaq: MBIS) is a leading Internet media company that provides services for social media, traditional media, and creative professionals, as well as for innovators in the 3D printing and mobile app industries. Service offerings include an online job board, news and analysis, trade shows and events, online and in-person courses, and research products.

All current Mediabistro Inc. press releases can be found online at:
http://corporate.mediabistro.com/corporate/press.html?c=mbprel

(SOFO) New Capture and Aggregation Tools Mediasite Enterprise Video Platform

InfoComm Booth #3059/UBTech Booth #400 — Sonic Foundry, Inc. (NASDAQ: SOFO), the trusted leader for video content management and webcasting solutions, announces the significant enhancements to its Mediasite Enterprise Video Platform, introducing the most advanced, open and enterprise-wide approach to creating, uploading, managing and distributing all video-based content.

Join us at Sonic Foundry’s press conference at InfoComm, Booth #3059 today at 9:30 am EDT, for a preview and demo of the latest innovations.

“The day is quickly approaching where everything that’s important on your campus or in the enterprise will be documented with video. With Mediasite Enterprise Video Platform we’ve engineered a video ecosystem that’s secure, searchable, easily managed and open to multiple content sources,” said Rob Lipps, executive vice president of Sonic Foundry. “We’ve helped our customers push the boundaries of advanced use-cases through automation and ubiquity, helping them achieve comprehensive capture, regardless of the video source.”

Enhancements to Mediasite Enterprise Video Platform include:

Multi-format video capture with synchronized automation of multiple video signals. Two or more videos can simultaneously stream within its intelligent multi-window Mediasite Player. It’s the most efficient and effective way to capture and live-stream multiple camera angles, complex procedures, simulations or training including:

• Collaborative classrooms and conference room discussions
• Simulations for medical, engineering or technology training
• Role-play scenarios such as moot court and practice interviews

“Mediasite 7’s ability to select any combination of cameras to be captured and streamed simultaneously will be helpful for role-playing student interviews and focus group research.”
~Asa Kelley, media technician, Bloomsburg University of Pennsylvania.

“Being able to capture and live stream any business-process video you can imagine while maintaining intimacy with the presenter is important for us.”
~Tom Aquilone, enterprise technology programs manager, Lockheed Martin.

Mediasite ML HD Recorder for event capture and on-the-go webcasting is the lightest, leanest portable webcasting appliance in its class. Fifty percent smaller than its predecessor the ML HD Recorder pairs maximum mobility with rugged design to meet the needs of the most demanding webcasting environments.

Centralized, full spectrum recording model cost-effectively extends the power of video to any room, automatically extracting video from sources such as IP cameras and video conferencing tools. Once video is uploaded to Mediasite’s Centralized Recorder it’s combined and synchronized with visual aids for a complete rich video experience. This reduces the cost-barriers of introducing technology to low-tech rooms by eliminating the need for expensive control systems.

“Until now affordable solutions to outfit all classrooms have been sorely missing. Sonic Foundry has addressed that problem – and this full-spectrum deployment model gets the higher education community one step closer to a situation in which lecture capture can be deployed intelligently and with agility and scale to an entire campus – even classrooms that might have in the past been overlooked.”
~ Alan D. Greenberg, senior analyst & partner, Wainhouse Research.

Mediasite’s powerful Voice Search Service pairs phonetic search with custom word lists, enabling users to accurately search and discover contextually relevant content contained in any video. As a result, users can efficiently pinpoint specific keywords contained in rapidly growing video libraries being used for learning, outreach and professional development.

My Mediasite, a streamlined, user-friendly interface from which users create, upload, manage and share their own video content. Collaboration and approval workflows provide a layer of control for enterprises with multiple content producers and knowledge-creation environments, allowing the growth, management and scalability of online knowledge libraries.

Mobile upload, giving users the ability to upload content directly to Mediasite from any mobile device or any video format, including Adobe Flash, QuickTime, AVI, Windows Media, MPEG4 and others, and transform them into rich video files that are indexed, searched, secured and played back on nearly any device from desktops and tablets to smart phones.

“Within the two major markets of the AV industry, education and workplace, there are major changes occurring today that profoundly affect the nature of the built environment and the technology needed to support the occupants of these buildings, namely students and workers, respectively. Capture technology is morphing to accommodate these more collaborative environments and complex simulations,” said Scott Walker, president and CEO of Waveguide Consulting.

These innovations will be demonstrated at InfoComm Booth #3059 and UBTech Booth #400.

About Sonic Foundry®, Inc.

Sonic Foundry (NASDAQ: SOFO) is the trusted market leader for enterprise webcasting solutions, providing video content management and distribution for education, business and government. Powered by the patented Mediasite webcasting platform and webcast services of Mediasite Events, the company empowers people to advance how they share knowledge online, using video webcasts to bridge time and distance, enhance learning outcomes and improve performance.

Product and service names mentioned herein are the trademarks of Sonic Foundry, Inc. or their respective owners.

Certain statements contained in this news release regarding matters that are not historical facts may be forward-looking statements. Because such forward-looking statements include risks and uncertainties, actual results may differ materially from those expressed in or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties pertaining to continued market acceptance for Sonic Foundry’s products, its ability to succeed in capturing significant revenues from media services and/or systems, the effect of new competitors in its market, integration of acquired business and other risk factors identified from time to time in its filings with the Securities and Exchange Commission.

Navidea (NAVB) Presentation of Meta-Analysis Results on Lymphoseek®

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results from a meta-analysis study of Lymphoseek^® (technetium Tc 99m tilmanocept) Injection, a novel, receptor-targeted, small-molecule radiopharmaceutical. The study compared Lymphoseek performance data from a pre-planned interim analysis of its Phase 3 clinical trial (NEO3-06) versus published data from the ACOSOG Z-0360 trial which was done using radiolabeled sulfur colloid. Results in this study demonstrated that Lymphoseek identified sentinel lymph nodes (SLNs) in subjects with squamous cell carcinoma of the head or neck (SCC) with a False Negative Rate (FNR) of 2.56%, whereas sulfur colloid demonstrated an FNR of 10% (p=0.0006). Lymphoseek identified SLNs with an overall accuracy of 99%, versus an overall accuracy of sulfur colloid of 97%. Dr. Francisco J. Civantos, MD, FACS, University of Miami School of Medicine, Miami, Fla., presented the results in an oral presentation at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver, Canada.

“False negative rates and overall accuracy are key metrics used to define the potential for performance of radiolabeled agents in lymphatic mapping and the evaluation of nodal metastasis. We believe the fact that Lymphoseek achieved statistically significant results, with a false negative rate of only 2.56% and 99% overall accuracy, attests to the performance of the product in identifying the appropriate tumor-draining lymph nodes,” said Frederick O. Cope, PhD, Senior Vice President and Chief Scientific Officer at Navidea.

“The removal of minimal lymph tissue while obtaining appropriate information as to whether cancer has spread is one of the key goals of sentinel lymph node biopsy, because approximately 75% of head and neck cancer patients may have pathology-negative lymph nodes and therefore do not require surgical removal of the full regional lymph node chain, as is a typical practice currently,” commented Dr. Civantos. “New receptor-targeted radiopharmaceuticals such as technetium-labeled tilmanocept may facilitate the diagnostic evaluation of these patients, to help spare them possible serious morbidity from full regional lymph node dissections.”

“We are pleased that we could present results from this comparative meta-analysis with Lymphoseek to the nuclear medicine physicians and industry experts at SNMMI, as thousands of patients with head and neck cancer stand to benefit from accurate diagnostic evaluation of their condition. The study uses top-line results from our interim analysis of Lymphoseek in the NEO3-06 Phase 3 clinical trial in head and neck cancer, and those developed in a widely regarded, independent, multi-center study,” said Mark Pykett, VMD, PhD, CEO of Navidea. “Our NEO3-06 Phase 3 trial is an important clinical trial in highlighting our belief that Lymphoseek may provide advances that could benefit thousands of patients with head and neck cancer. Assessment of the full data-set from the NEO3-06 trial continues, and we are working with the FDA to evaluate the submission of a supplemental NDA that may potentially augment the Lymphoseek label.”

About the Meta-analysis

The study used meta-analysis to examine two key parameters for assessing performance of radiotracing agents in lymphatic mapping and the evaluation of nodal metastasis in SCC: False Negative Rate (FNR), the percentage of patients in whom the sentinel lymph node failed to correctly stage the patient; and overall accuracy (AC), the degree of correctness. All patients in both studies received sentinel lymph node biopsy and complete, elective dissection of head and neck lymph nodes, and all nodes were evaluated for the presence of tumor. Results for Lymphoseek indicated a FNR of 0.0256 (95% CI=0.001, 0.138; n=39); p<0.0006 as compared to radiolabeled sulfur colloid; the FNR for radiolabeled sulfur colloid was 0.10 (95% CI=0.027, 0.231; n=41). Overall accuracy for Lymphoseek was 0.99 (n=82; P<0.0161 against radiolabeled sulfur colloid). The overall accuracy for radiolabeled sulfur colloid was 0.97 (n=140).

About Lymphoseek^®

Lymphoseek^® (technetium Tc 99m tilmanocept) Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical used in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. Lymphoseek was approved by the U.S. Food and Drug Administration in March, 2013 for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma. The Company anticipates continuing development of Lymphoseek into other solid tumor areas that may include head and neck cancers, prostate cancer, thyroid cancer, lung/bronchus cancers, colorectal cancer and others.

Accurate diagnostic evaluation of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. According to the American Cancer Society, approximately 232,000 new cases of breast cancer, 77,000 new cases of melanoma and 67,000 new cases of head and neck/oral cancer are expected to be diagnosed in the United States in 2013.

U.S. Indication and Important Safety Information About Lymphoseek

Indication

Lymphoseek (technetium Tc 99m tilmanocept) Injection is a lymphatic mapping agent indicated for use with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma.

Important Safety Information

In clinical trials with Lymphoseek, no serious hypersensitivity reactions were reported, however Lymphoseek may pose a risk of such reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs).

Prior to the administration of Lymphoseek, patients should be asked about previous hypersensitivity reactions to drugs, in particular dextran and modified forms of dextran. Resuscitation equipment and trained personnel should be available at the time of Lymphoseek administration, and patients observed for signs or symptoms of hypersensitivity following injection.

The most common adverse reactions are injection site irritation and/or pain (<1%).

FULL LYMPHOSEEK PRESCRIBING INFORMATION CAN BE FOUND AT:
WWW.LYMPHOSEEK.COM

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek^®, NAV4694, NAV5001 and RIGScan^TM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements within the meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

(AMRI) CEO to Present at the 2013 Wells Fargo Securities Healthcare Conference

ALBANY, N.Y., June 12, 2013 /PRNewswire/ — AMRI (NASDAQ: AMRI) announced today that Thomas E. D’Ambra, Ph.D., President and Chief Executive Officer at AMRI, will present at the 2013 Wells Fargo Securities Healthcare Conference on Wednesday, June 19, 2013 at 10:40 a.m. ET.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).